A group of disorders marked by progressive degeneration of motor neurons in the spinal cord resulting in weakness and muscular atrophy, usually without evidence of injury to the corticospinal tracts. Diseases in this category include Werdnig-Hoffmann disease and later onset SPINAL MUSCULAR ATROPHIES OF CHILDHOOD, most of which are hereditary. (Adams et al., Principles of Neurology, 6th ed, p1089)
A group of recessively inherited diseases that feature progressive muscular atrophy and hypotonia. They are classified as type I (Werdnig-Hoffman disease), type II (intermediate form), and type III (Kugelberg-Welander disease). Type I is fatal in infancy, type II has a late infantile onset and is associated with survival into the second or third decade. Type III has its onset in childhood, and is slowly progressive. (J Med Genet 1996 Apr:33(4):281-3)
A SMN complex protein that is essential for the function of the SMN protein complex. In humans the protein is encoded by a single gene found near the inversion telomere of a large inverted region of CHROMOSOME 5. Mutations in the gene coding for survival of motor neuron 1 protein may result in SPINAL MUSCULAR ATROPHIES OF CHILDHOOD.
A complex of proteins that assemble the SNRNP CORE PROTEINS into a core structure that surrounds a highly conserved RNA sequence found in SMALL NUCLEAR RNA. They are found localized in the GEMINI OF COILED BODIES and in the CYTOPLASM. The SMN complex is named after the Survival of Motor Neuron Complex Protein 1, which is a critical component of the complex.
A SMN complex protein that is closely-related to SURVIVAL OF MOTOR NEURON 1 PROTEIN. In humans, the protein is encoded by an often duplicated gene found near the inversion centromere of a large inverted region of CHROMOSOME 5.
Derangement in size and number of muscle fibers occurring with aging, reduction in blood supply, or following immobilization, prolonged weightlessness, malnutrition, and particularly in denervation.
Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
An inhibitor of apoptosis protein that was initially identified during analysis of CHROMOSOME DELETIONS associated with SPINAL MUSCULAR ATROPHY. Naip contains a nucleotide binding oligomerization domain and a carboxy-terminal LEUCINE rich repeat.
A cylindrical column of tissue that lies within the vertebral canal. It is composed of WHITE MATTER and GRAY MATTER.
A protein that has been shown to function as a calcium-regulated transcription factor as well as a substrate for depolarization-activated CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES. This protein functions to integrate both calcium and cAMP signals.
Proteins that bind to RNA molecules. Included here are RIBONUCLEOPROTEINS and other proteins whose function is to bind specifically to RNA.
Neurons which activate MUSCLE CELLS.
MOTOR NEURONS in the anterior (ventral) horn of the SPINAL CORD which project to SKELETAL MUSCLES.
'Nerve tissue proteins' are specialized proteins found within the nervous system's biological tissue, including neurofilaments, neuronal cytoskeletal proteins, and neural cell adhesion molecules, which facilitate structural support, intracellular communication, and synaptic connectivity essential for proper neurological function.
Highly conserved nuclear RNA-protein complexes that function in RNA processing in the nucleus, including pre-mRNA splicing and pre-mRNA 3'-end processing in the nucleoplasm, and pre-rRNA processing in the nucleolus (see RIBONUCLEOPROTEINS, SMALL NUCLEOLAR).
A multifunctional protein that is both a DEAD-box RNA helicase and a component of the SMN protein complex.
Disorders characterized by an abnormal reduction in muscle volume due to a decrease in the size or number of muscle fibers. Atrophy may result from diseases intrinsic to muscle tissue (e.g., MUSCULAR DYSTROPHY) or secondary to PERIPHERAL NERVOUS SYSTEM DISEASES that impair innervation to muscle tissue (e.g., MUSCULAR ATROPHY, SPINAL).
One of the two pairs of human chromosomes in the group B class (CHROMOSOMES, HUMAN, 4-5).
An X-linked recessive form of spinal muscular atrophy. It is due to a mutation of the gene encoding the ANDROGEN RECEPTOR.
Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).
The parts of a transcript of a split GENE remaining after the INTRONS are removed. They are spliced together to become a MESSENGER RNA or other functional RNA.
A distinct subnuclear domain enriched in splicesomal snRNPs (RIBONUCLEOPROTEINS, SMALL NUCLEAR) and p80-coilin.
The protein components that constitute the common core of small nuclear ribonucleoprotein particles. These proteins are commonly referred as Sm nuclear antigens due to their antigenic nature.
Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)
Pathologic conditions which feature SPINAL CORD damage or dysfunction, including disorders involving the meninges and perimeningeal spaces surrounding the spinal cord. Traumatic injuries, vascular diseases, infections, and inflammatory/autoimmune processes may affect the spinal cord.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
The record of descent or ancestry, particularly of a particular condition or trait, indicating individual family members, their relationships, and their status with respect to the trait or condition.
Identification of genetic carriers for a given trait.
An enzyme that activates glycine with its specific transfer RNA. EC 6.1.1.14.
A genetic rearrangement through loss of segments of DNA or RNA, bringing sequences which are normally separated into close proximity. This deletion may be detected using cytogenetic techniques and can also be inferred from the phenotype, indicating a deletion at one specific locus.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
Conditions characterized by impaired transmission of impulses at the NEUROMUSCULAR JUNCTION. This may result from disorders that affect receptor function, pre- or postsynaptic membrane function, or ACETYLCHOLINESTERASE activity. The majority of diseases in this category are associated with autoimmune, toxic, or inherited conditions.
The ultimate exclusion of nonsense sequences or intervening sequences (introns) before the final RNA transcript is sent to the cytoplasm.
An individual in which both alleles at a given locus are identical.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
A subtype of striated muscle, attached by TENDONS to the SKELETON. Skeletal muscles are innervated and their movement can be consciously controlled. They are also called voluntary muscles.
Atrophy of the optic disk which may be congenital or acquired. This condition indicates a deficiency in the number of nerve fibers which arise in the RETINA and converge to form the OPTIC DISK; OPTIC NERVE; OPTIC CHIASM; and optic tracts. GLAUCOMA; ISCHEMIA; inflammation, a chronic elevation of intracranial pressure, toxins, optic nerve compression, and inherited conditions (see OPTIC ATROPHIES, HEREDITARY) are relatively common causes of this condition.
Persistent flexure or contracture of a joint.
The synapse between a neuron and a muscle.
The number of copies of a given gene present in the cell of an organism. An increase in gene dosage (by GENE DUPLICATION for example) can result in higher levels of gene product formation. GENE DOSAGE COMPENSATION mechanisms result in adjustments to the level GENE EXPRESSION when there are changes or differences in gene dosage.
Nerve fibers that are capable of rapidly conducting impulses away from the neuron cell body.
Prolonged shortening of the muscle or other soft tissue around a joint, preventing movement of the joint.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Recording of the changes in electric potential of muscle by means of surface or needle electrodes.
A general term encompassing lower MOTOR NEURON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; and certain MUSCULAR DISEASES. Manifestations include MUSCLE WEAKNESS; FASCICULATION; muscle ATROPHY; SPASM; MYOKYMIA; MUSCLE HYPERTONIA, myalgias, and MUSCLE HYPOTONIA.
Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
Genes that influence the PHENOTYPE only in the homozygous state.
The branch of chemistry dealing with detection (qualitative) and determination (quantitative) of substances. (Grant & Hackh's Chemical Dictionary, 5th ed)
A hereditary motor and sensory neuropathy transmitted most often as an autosomal dominant trait and characterized by progressive distal wasting and loss of reflexes in the muscles of the legs (and occasionally involving the arms). Onset is usually in the second to fourth decade of life. This condition has been divided into two subtypes, hereditary motor and sensory neuropathy (HMSN) types I and II. HMSN I is associated with abnormal nerve conduction velocities and nerve hypertrophy, features not seen in HMSN II. (Adams et al., Principles of Neurology, 6th ed, p1343)
Determination of the nature of a pathological condition or disease in the postimplantation EMBRYO; FETUS; or pregnant female before birth.
Involuntary contraction of the muscle fibers innervated by a motor unit. Fasciculations can often by visualized and take the form of a muscle twitch or dimpling under the skin, but usually do not generate sufficient force to move a limb. They may represent a benign condition or occur as a manifestation of MOTOR NEURON DISEASE or PERIPHERAL NERVOUS SYSTEM DISEASES. (Adams et al., Principles of Neurology, 6th ed, p1294)
Genes that influence the PHENOTYPE both in the homozygous and the heterozygous state.
Congenital or acquired paralysis of one or both VOCAL CORDS. This condition is caused by defects in the CENTRAL NERVOUS SYSTEM, the VAGUS NERVE and branches of LARYNGEAL NERVES. Common symptoms are VOICE DISORDERS including HOARSENESS or APHONIA.
Introduction of therapeutic agents into the spinal region using a needle and syringe.
The co-inheritance of two or more non-allelic GENES due to their being located more or less closely on the same CHROMOSOME.
Paired bundles of NERVE FIBERS entering and leaving the SPINAL CORD at each segment. The dorsal and ventral nerve roots join to form the mixed segmental spinal nerves. The dorsal roots are generally afferent, formed by the central projections of the spinal (dorsal root) ganglia sensory cells, and the ventral roots are efferent, comprising the axons of spinal motor and PREGANGLIONIC AUTONOMIC FIBERS.
An educational process that provides information and advice to individuals or families about a genetic condition that may affect them. The purpose is to help individuals make informed decisions about marriage, reproduction, and other health management issues based on information about the genetic disease, the available diagnostic tests, and management programs. Psychosocial support is usually offered.
Organelles in which the splicing and excision reactions that remove introns from precursor messenger RNA molecules occur. One component of a spliceosome is five small nuclear RNA molecules (U1, U2, U4, U5, U6) that, working in conjunction with proteins, help to fold pieces of RNA into the right shapes and later splice them into the message.
A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)
A process whereby multiple RNA transcripts are generated from a single gene. Alternative splicing involves the splicing together of other possible sets of EXONS during the processing of some, but not all, transcripts of the gene. Thus a particular exon may be connected to any one of several alternative exons to form a mature RNA. The alternative forms of mature MESSENGER RNA produce PROTEIN ISOFORMS in which one part of the isoforms is common while the other parts are different.
Complete or severe weakness of the muscles of respiration. This condition may be associated with MOTOR NEURON DISEASES; PERIPHERAL NERVE DISEASES; NEUROMUSCULAR JUNCTION DISEASES; SPINAL CORD DISEASES; injury to the PHRENIC NERVE; and other disorders.
The propagation of the NERVE IMPULSE along the nerve away from the site of an excitation stimulus.
A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of voltage dependent sodium channels.
The 31 paired peripheral nerves formed by the union of the dorsal and ventral spinal roots from each spinal cord segment. The spinal nerve plexuses and the spinal roots are also included.
Detection of a MUTATION; GENOTYPE; KARYOTYPE; or specific ALLELES associated with genetic traits, heritable diseases, or predisposition to a disease, or that may lead to the disease in descendants. It includes prenatal genetic testing.
A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92)
Procedure in which an anesthetic is injected directly into the spinal cord.
An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.
An infant during the first month after birth.
The physical activity of a human or an animal as a behavioral phenomenon.
Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA.
A heterogeneous group of inherited MYOPATHIES, characterized by wasting and weakness of the SKELETAL MUSCLE. They are categorized by the sites of MUSCLE WEAKNESS; AGE OF ONSET; and INHERITANCE PATTERNS.
Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
A mutation in which a codon is mutated to one directing the incorporation of a different amino acid. This substitution may result in an inactive or unstable product. (From A Dictionary of Genetics, King & Stansfield, 5th ed)
The cavity within the SPINAL COLUMN through which the SPINAL CORD passes.
A group of slowly progressive inherited disorders affecting motor and sensory peripheral nerves. Subtypes include HMSNs I-VII. HMSN I and II both refer to CHARCOT-MARIE-TOOTH DISEASE. HMSN III refers to hypertrophic neuropathy of infancy. HMSN IV refers to REFSUM DISEASE. HMSN V refers to a condition marked by a hereditary motor and sensory neuropathy associated with spastic paraplegia (see SPASTIC PARAPLEGIA, HEREDITARY). HMSN VI refers to HMSN associated with an inherited optic atrophy (OPTIC ATROPHIES, HEREDITARY), and HMSN VII refers to HMSN associated with retinitis pigmentosa. (From Adams et al., Principles of Neurology, 6th ed, p1343)
Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions.
A class of closely related heterogeneous-nuclear ribonucleoproteins of approximately 34-40 kDa in size. Although they are generally found in the nucleoplasm, they also shuttle between the nucleus and the cytoplasm. Members of this class have been found to have a role in mRNA transport, telomere biogenesis and RNA SPLICING.
'Spinal diseases' is a broad term referring to various medical conditions that affect the structural integrity, function, or health of the spinal column, including degenerative disorders, infections, inflammatory processes, traumatic injuries, neoplasms, and congenital abnormalities.
The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for VIRUS CULTIVATION and antitumor drug screening assays.
Acute and chronic conditions characterized by external mechanical compression of the SPINAL CORD due to extramedullary neoplasm; EPIDURAL ABSCESS; SPINAL FRACTURES; bony deformities of the vertebral bodies; and other conditions. Clinical manifestations vary with the anatomic site of the lesion and may include localized pain, weakness, sensory loss, incontinence, and impotence.
A device that measures MUSCLE STRENGTH during muscle contraction, such as gripping, pushing, and pulling. It is used to evaluate the health status of muscle in sports medicine or physical therapy.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
Spinal neoplasms are abnormal growths or tumors that develop within the spinal column, which can be benign or malignant, and originate from cells within the spinal structure or spread to the spine from other parts of the body (metastatic).
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
An individual having different alleles at one or more loci regarding a specific character.
Any method used for determining the location of and relative distances between genes on a chromosome.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
Bulbous enlargement of the growing tip of nerve axons and dendrites. They are crucial to neuronal development because of their pathfinding ability and their role in synaptogenesis.
Contractile tissue that produces movement in animals.
Biochemical identification of mutational changes in a nucleotide sequence.
Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize.
A motor neuron disease marked by progressive weakness of the muscles innervated by cranial nerves of the lower brain stem. Clinical manifestations include dysarthria, dysphagia, facial weakness, tongue weakness, and fasciculations of the tongue and facial muscles. The adult form of the disease is marked initially by bulbar weakness which progresses to involve motor neurons throughout the neuroaxis. Eventually this condition may become indistinguishable from AMYOTROPHIC LATERAL SCLEROSIS. Fazio-Londe syndrome is an inherited form of this illness which occurs in children and young adults. (Adams et al., Principles of Neurology, 6th ed, p1091; Brain 1992 Dec;115(Pt 6):1889-1900)

Prenatal diagnosis of spinal muscular atrophy type I (Werdnig- hoffmann) by DNA deletion analysis of cultivated amniocytes. (1/127)

AIM: Presentation of a prenatally diagnosed case of Werdnig-Hoffmann disease, the most severe type of spinal muscular atrophy. METHODS: DNA obtained from cultivated amniocytes was analyzed for deletions in the survival motor neuron gene and neuronal apoptosis inhibitory protein gene. RESULTS: The fetus was diagnosed as an affected homozygote for deletions in exon 7 and exon 8 of the survival motor neuron gene. No deletions of exon 5 in the neuronal apoptosis inhibitory protein gene were found. CONCLUSION: Direct DNA deletion analysis of the survival motor neuron gene and neuronal apoptosis inhibitory protein gene in affected families represents a highly reliable and fast method for prenatal diagnosis of Werdnig-Hoffmann disease.  (+info)

Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for spinal muscular atrophy type III. (2/127)

Spinal muscular atrophy (SMA) is caused by deletion or specific mutations of the telomeric survival motor neuron ( SMN ) gene on human chromosome 5. The human SMN gene, in contrast to the Smn gene in mouse, is duplicated and the centromeric copy on chromosome 5 codes for transcripts which preferentially lead to C-terminally truncated SMN protein. Here we show that a 46% reduction of Smn protein levels in the spinal cord of Smn heterozygous mice leads to a marked loss of the cytoplasmic Smn pool and motor neuron degeneration resembling spinal muscular atrophy type 3. Smn heterozygous mice described here thus represent a model for the human disease. These mice could allow screening for SMA therapies and help in gaining further understanding of the pathophysiological events leading to motor neuron degeneration in SMA.  (+info)

Juvenile muscular atrophy of distal upper extremity (Hirayama disease). (3/127)

This disease is characterized by initially progressive muscular weakness and wasting of the distal upper limb(s) in young people predominantly in men, followed by a spontaneous arrest within several years. This disease has been thought to be separate from motor neuron diseases, yet some authors still consider the illness a variant of motor neuron disease. However, the pathological evidence of ischemic changes in the lower cervical anterior horn should facilitate differentiation of the disorder from degenerative motor neuron disease. Recent radiological investigations proved compressive flattening of the lower cervical cord due to forward displacement of the cervical dural sac and spinal cord induced by neck flexion. These findings suggest that sustained or repeated neck flexion may cause ischemic changes in the cervical anterior horn. Application of a cervical collar to minimize neck flexion prevents progressive muscular weakness in an early stage of the disease.  (+info)

An essential SMN interacting protein (SIP1) is not involved in the phenotypic variability of spinal muscular atrophy (SMA). (4/127)

The survival motor neuron (SMN) protein and the SMN interacting protein 1 (SIP1) are part of a 300 kD protein complex with a crucial role in snRNP biogenesis and pre-mRNA splicing. Both proteins are colocalised in nuclear structures called gems and in the cytoplasm. Approximately 96% of patients with autosomal recessive spinal muscular atrophy (SMA) show mutations in the SMN1 gene, while about 4% fail to show any mutation, despite a typical SMA phenotype. Additionally, sibs with identical 5q13 homologs and homozygous absence of SMN1 can show variable phenotypes which suggest that SMA is modified by other, yet unknown factors. Since both genes, SMN1 and SIP1, belong to the same pathway and are part of the same protein complex, it is obvious to ask whether mutations within SIP1 are responsible for both the phenotypic variability and the appearance of non-SMN mutated SMA patients. First, we identified the chromosomal location of SIP1 and assigned it to chromosomal region 14q13-q21 by fluorescence in situ hybridisation. No SMA related disorder has yet been assigned to this chromosomal region. Next, we determined the exon-intron structure of the SIP1 gene which encompasses 10 exons and identified five transcription isoforms. We sequenced either RT-PCR products or genomic DNA covering the complete coding region from 23 typical SMA patients who had failed to show any SMN1 mutation. No mutation and no polymorphism was found within SIP1. Additionally, we sequenced RT-PCR products or genomic fragments of the entire SIP1 coding region from 26 sibs of 11 SMA families with identical genotypes (delta7SMN/delta7SMN or delta7SMN/other mutation) but different phenotypes and again no mutation was found. Finally, we performed quantitative analysis of RT-PCR products from the same 26 sibs. No difference in expression level of the five isoforms among phenotypically variable sibs was observed. Based on these data, we suggest that neither the phenotypic variability nor the 5q-unlinked SMA are caused by mutations within SIP1.  (+info)

Non-progressive juvenile spinal muscular atrophy of the distal upper limb (Hirayama's disease): a clinical variant of the benign monomelic amyotrophy. (5/127)

Hirayama's disease (HD) is frequently found in Asia, and is rarely referred among westerners. It affects young people with higher incidence in males. It is a focal distal amyotrophy with unilateral or asymmetric bilateral involvement of C7, C8 and T1 innervated muscles. HD appears sporadically and has a benign evolution with clinical stabilization in around one year. We report four young male patients with clinical and electrophysiological alterations described in HD, which were followed-up during 5 years. Electromyographic findings were indicative of lower motor neuron involvement. We analyzed cervical MRI aiming at understanding if a questionable spinal cord compression could be implicated in the pathogenesis, but no abnormality was verified. In view of its clinical, and EMG characteristics, HD is no more than a benign monomelic amyotrophy (BMA) clinical variant, and not a specific disease. This eponym could be considered only for the distal upper limb variant (Hirayama's variant) of the BMA.  (+info)

Correlation between genotype and phenotype in Korean patients with spinal muscular atrophy. (6/127)

The goal of this study was to define the correlation between genotype and phenotype in Korean patients with spinal muscular atrophy (SMA). The SMA can be classified into three groups based on the age of onset and the clinical course. The candidate genes, survival motor neuron (SMN) gene, neuronal apoptosis inhibitory protein (NAIP) gene, and p44 gene were mapped and duplicated with telomeric and centromeric. The loss of the telomeric SMN occurs by a different mechanism. That is the deletion or conversion of telomeric SMN to centromeric SMN, in which case the conversion could produce a mild phenotype and deletion could produce a severe one. It has been known that there may be a balance between the numbers of copies expressed by the centromeric and telomeric SMN genes. In our study, ten patients with type I SMA and two type II patients were identified by their clinical findings and DNA studies. The major deletion of SMA candidate genes, deletion of the SMN gene, NAIP gene, and p44 gene were identified in six patients with type I SMA, while the rest of type I and all the type II patients showed the deletion of the SMN gene only. Allele numbers of the C212 marker were compared in patients and normal controls in order to find the correlation between the copy numbers and the clinical severity. The result was that type I patients had 2-5 alleles and the normal controls had 4-6. This suggests that the deletion is a major determining factor in the clinical phenotype. However, two type I patients with telomeric NAIP gene deletion notably had 4-5 alleles, as in the normal controls. This result implies that the correlation between the copy numbers and the severity is uncertain as opposed to the previous hypothesis. One type I patient showed the conversion of the centromeric SMN gene to the telomeric, which supports the conclusion that gene conversion is an important molecular mechanism for SMA. In the study of one hundred normal newborns, two physically normal newborns showed deletion of the centromeric SMN gene, suggesting frequent rearrangement in the locus.  (+info)

Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. (7/127)

Proximal spinal muscular atrophy (SMA) is a common motor neuron disorder caused by mutation of the telomeric survival of motor neuron gene SMN1. The centromeric survival of motor neuron SMN2 gene is retained in all SMA patients but does not produce sufficient SMN protein to prevent the development of clinical symptoms. The SMN1 and SMN2 genes differ functionally by a single nucleotide change. This change affects the efficiency with which exon 7 is incorporated into the mRNA transcript. Thus, SMN2 produces less full-length mRNA and protein than SMN1. We have screened a library of compounds in order to identify ones that can alter the splicing pattern of the SMN2 gene. Here, we report that the compound aclarubicin increases the retention of exon 7 into the SMN2 transcript. We show that aclarubicin effectively induces incorporation of exon 7 into SMN2 transcripts from the endogenous gene in type I SMA fibroblasts as well as into transcripts from a SMN2 minigene in the motor neuron cell line NSC34. In type I fibroblasts, treatment resulted in an increase in SMN protein and gems to normal levels. Our results suggest that alteration of splicing pattern represents a new approach to modification of gene expression in disease treatment and demonstrate the feasibility of high throughput screens to detect compounds that affect the splicing pattern of a gene.  (+info)

Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord. (8/127)

Spinal muscular atrophy (SMA) is an autosomal recessive disorder caused by mutations in the survival motor neurone gene (SMN). The degeneration and loss of the anterior horn cells is the major neuropathological finding in SMA, but the mechanism and timing of this abnormal motor neurone death remain unknown. A quantitative study was carried out comparing neuronal death in controls and SMA foetuses and neonates. Between 12 and 15 weeks of gestational age, a significant increase in nuclear DNA vulnerability, as revealed with the method of in situ end-labelling of nuclear DNA fragmentation, was detected in SMA foetuses and was reflected by a decrease in the number of neurones of the anterior horn. Neurones with nuclear DNA vulnerability are no longer detected at the end of the foetal period and the post-natal period. On the other hand, abnormal morphology of motor neurones, mainly early chromatolytic changes, was observed only after birth. Our findings indicate that in type I SMA, the absence or dysfunction of SMN is reflected by an enhanced neuronal death that is already detectable at 12 weeks, the earliest SMA foetal stage analysed. This is associated with a progressive loss of motor neurones towards the neonatal period. Given that a proportion of the remaining SMA motor neurones in the neonatal period appear with pathological findings not detected at earlier stages, it can be hypothesized that type I SMA results in differential age-dependent responses leading to cell death and motor neurone degeneration during development.  (+info)

Spinal muscular atrophy (SMA) is a genetic disorder that affects the motor neurons in the spinal cord, leading to muscle weakness and atrophy. It is caused by a mutation in the survival motor neuron 1 (SMN1) gene, which results in a deficiency of SMN protein necessary for the survival of motor neurons.

There are several types of SMA, classified based on the age of onset and severity of symptoms. The most common type is type 1, also known as Werdnig-Hoffmann disease, which presents in infancy and is characterized by severe muscle weakness, hypotonia, and feeding difficulties. Other types include type 2 (intermediate SMA), type 3 (Kugelberg-Welander disease), and type 4 (adult-onset SMA).

The symptoms of SMA may include muscle wasting, fasciculations, weakness, hypotonia, respiratory difficulties, and mobility impairment. The diagnosis of SMA typically involves genetic testing to confirm the presence of a mutation in the SMN1 gene. Treatment options for SMA may include medications, physical therapy, assistive devices, and respiratory support.

Spinal muscular atrophies (SMAs) of childhood are a group of inherited neuromuscular disorders characterized by degeneration and loss of lower motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. The severity and age of onset can vary significantly, with some forms presenting in infancy and others in later childhood or even adulthood.

The most common form of SMA is 5q autosomal recessive SMA, also known as survival motor neuron (SMN) disease, which results from mutations in the SMN1 gene. The severity of this form can range from severe (type I or Werdnig-Hoffmann disease), intermediate (type II or chronic infantile neurodegenerative disorder), to mild (type III or Kugelberg-Welander disease).

Type I SMA is the most severe form, with onset before 6 months of age and rapid progression leading to death within the first two years of life if left untreated. Type II SMA has an onset between 6 and 18 months of age, with affected children never achieving the ability to walk independently. Type III SMA has a later onset, typically after 18 months of age, and is characterized by a slower progression, allowing for the ability to walk unaided, although mobility may be lost over time.

Other forms of childhood-onset SMA include autosomal dominant distal SMA, X-linked SMA, and spinal bulbar muscular atrophy (SBMA or Kennedy's disease). These forms have distinct genetic causes and clinical presentations.

In general, SMAs are characterized by muscle weakness, hypotonia, fasciculations, tongue atrophy, and depressed or absent deep tendon reflexes. Respiratory and nutritional support is often required in more severe cases. Recent advances in gene therapy have led to the development of disease-modifying treatments for some forms of SMA.

Survival of Motor Neuron 1 (SMN1) protein is a critical component for the survival of motor neurons, which are nerve cells that control muscle movements. The SMN1 protein is produced by the Survival of Motor Neuron 1 gene, located on human chromosome 5q13.

The primary function of the SMN1 protein is to assist in the biogenesis of small nuclear ribonucleoproteins (snRNPs), which are essential for spliceosomes - complex molecular machines responsible for RNA processing in the cell. The absence or significant reduction of SMN1 protein leads to defective snRNP assembly, impaired RNA splicing, and ultimately results in motor neuron degeneration.

Mutations in the SMN1 gene can cause Spinal Muscular Atrophy (SMA), a genetic disorder characterized by progressive muscle weakness, atrophy, and paralysis due to the loss of lower motor neurons in the spinal cord. The severity of SMA depends on the amount of functional SMN1 protein produced, with less protein leading to more severe symptoms.

The Survival Motor Neuron (SMN) complex is a protein complex that plays a crucial role in the biogenesis of small nuclear ribonucleoproteins (snRNPs), which are essential components of the spliceosome involved in pre-messenger RNA (pre-mRNA) splicing. The SMN complex consists of several proteins, including the SMN protein itself, Gemins2-8, and unrip.

The SMN protein is the central component of the complex and is encoded by the SMN1 gene located on chromosome 5q13.2. Mutations in this gene can lead to spinal muscular atrophy (SMA), a genetic disorder characterized by degeneration of motor neurons in the spinal cord, leading to muscle weakness and atrophy.

The SMN complex assembles in the cytoplasm and facilitates the assembly of spliceosomal snRNPs by helping to load Sm proteins onto small nuclear RNA (snRNA) molecules. Proper functioning of the SMN complex is essential for the correct splicing of pre-mRNA, and its dysfunction can lead to various developmental abnormalities and diseases, including SMA.

Survival of Motor Neuron 2 (SMN2) protein is a functional copy of the Survival of Motor Neuron (SMN) protein, which is produced from the SMN2 gene. The SMN protein is crucial for the survival of motor neurons, the nerve cells that control muscle movement. In people with spinal muscular atrophy (SMA), a genetic disorder that causes progressive muscle weakness and loss of movement, there is a mutation in the main SMN1 gene that leads to reduced levels of functional SMN protein.

The SMN2 gene can also produce some functional SMN protein, but it mainly produces an unstable, truncated form of the protein due to a critical difference in its exon 7 splicing pattern. However, a small percentage (about 10-15%) of SMN2 transcripts can be correctly spliced and produce full-length, functional SMN protein. The amount of functional SMN protein produced from the SMN2 gene is directly related to the severity of SMA; more SMN protein production from SMN2 leads to less severe symptoms. Therefore, therapies aimed at increasing SMN2-derived SMN protein levels are being developed and tested for the treatment of SMA.

Muscular atrophy is a condition characterized by a decrease in the size and mass of muscles due to lack of use, disease, or injury. This occurs when there is a disruption in the balance between muscle protein synthesis and degradation, leading to a net loss of muscle proteins. There are two main types of muscular atrophy:

1. Disuse atrophy: This type of atrophy occurs when muscles are not used or are immobilized for an extended period, such as after an injury, surgery, or prolonged bed rest. In this case, the nerves that control the muscles may still be functioning properly, but the muscles themselves waste away due to lack of use.
2. Neurogenic atrophy: This type of atrophy is caused by damage to the nerves that supply the muscles, leading to muscle weakness and wasting. Conditions such as amyotrophic lateral sclerosis (ALS), spinal cord injuries, and peripheral neuropathies can cause neurogenic atrophy.

In both cases, the affected muscles may become weak, shrink in size, and lose their tone and mass. Treatment for muscular atrophy depends on the underlying cause and may include physical therapy, exercise, and medication to manage symptoms and improve muscle strength and function.

Atrophy is a medical term that refers to the decrease in size and wasting of an organ or tissue due to the disappearance of cells, shrinkage of cells, or decreased number of cells. This process can be caused by various factors such as disuse, aging, degeneration, injury, or disease.

For example, if a muscle is immobilized for an extended period, it may undergo atrophy due to lack of use. Similarly, certain medical conditions like diabetes, cancer, and heart failure can lead to the wasting away of various tissues and organs in the body.

Atrophy can also occur as a result of natural aging processes, leading to decreased muscle mass and strength in older adults. In general, atrophy is characterized by a decrease in the volume or weight of an organ or tissue, which can have significant impacts on its function and overall health.

NAIP (Neuronal Apoptosis Inhibitory Protein) is a protein involved in inhibiting programmed cell death, also known as apoptosis. It is a member of the inhibitor of apoptosis (IAP) family and is primarily expressed in neurons. NAIP plays a crucial role in preventing excessive cell death during nervous system development and after nerve injury. It functions by binding to and inhibiting certain caspases, which are enzymes that play an essential role in initiating and executing apoptosis. Mutations in the gene encoding NAIP have been associated with neurodegenerative disorders such as spinal muscular atrophy and amyotrophic lateral sclerosis (ALS).

The spinal cord is a major part of the nervous system, extending from the brainstem and continuing down to the lower back. It is a slender, tubular bundle of nerve fibers (axons) and support cells (glial cells) that carries signals between the brain and the rest of the body. The spinal cord primarily serves as a conduit for motor information, which travels from the brain to the muscles, and sensory information, which travels from the body to the brain. It also contains neurons that can independently process and respond to information within the spinal cord without direct input from the brain.

The spinal cord is protected by the bony vertebral column (spine) and is divided into 31 segments: 8 cervical, 12 thoracic, 5 lumbar, 5 sacral, and 1 coccygeal. Each segment corresponds to a specific region of the body and gives rise to pairs of spinal nerves that exit through the intervertebral foramina at each level.

The spinal cord is responsible for several vital functions, including:

1. Reflexes: Simple reflex actions, such as the withdrawal reflex when touching a hot surface, are mediated by the spinal cord without involving the brain.
2. Muscle control: The spinal cord carries motor signals from the brain to the muscles, enabling voluntary movement and muscle tone regulation.
3. Sensory perception: The spinal cord transmits sensory information, such as touch, temperature, pain, and vibration, from the body to the brain for processing and awareness.
4. Autonomic functions: The sympathetic and parasympathetic divisions of the autonomic nervous system originate in the thoracolumbar and sacral regions of the spinal cord, respectively, controlling involuntary physiological responses like heart rate, blood pressure, digestion, and respiration.

Damage to the spinal cord can result in various degrees of paralysis or loss of sensation below the level of injury, depending on the severity and location of the damage.

CREB (Cyclic AMP Response Element-Binding Protein) is a transcription factor that plays a crucial role in regulating gene expression in response to various cellular signals. CREB binds to the cAMP response element (CRE) sequence in the promoter region of target genes and regulates their transcription.

When activated, CREB undergoes phosphorylation at a specific serine residue (Ser-133), which leads to its binding to the coactivator protein CBP/p300 and recruitment of additional transcriptional machinery to the promoter region. This results in the activation of target gene transcription.

CREB is involved in various cellular processes, including metabolism, differentiation, survival, and memory formation. Dysregulation of CREB has been implicated in several diseases, such as cancer, neurodegenerative disorders, and mood disorders.

RNA-binding proteins (RBPs) are a class of proteins that selectively interact with RNA molecules to form ribonucleoprotein complexes. These proteins play crucial roles in the post-transcriptional regulation of gene expression, including pre-mRNA processing, mRNA stability, transport, localization, and translation. RBPs recognize specific RNA sequences or structures through their modular RNA-binding domains, which can be highly degenerate and allow for the recognition of a wide range of RNA targets. The interaction between RBPs and RNA is often dynamic and can be regulated by various post-translational modifications of the proteins or by environmental stimuli, allowing for fine-tuning of gene expression in response to changing cellular needs. Dysregulation of RBP function has been implicated in various human diseases, including neurological disorders and cancer.

Motor neurons are specialized nerve cells in the brain and spinal cord that play a crucial role in controlling voluntary muscle movements. They transmit electrical signals from the brain to the muscles, enabling us to perform actions such as walking, talking, and swallowing. There are two types of motor neurons: upper motor neurons, which originate in the brain's motor cortex and travel down to the brainstem and spinal cord; and lower motor neurons, which extend from the brainstem and spinal cord to the muscles. Damage or degeneration of these motor neurons can lead to various neurological disorders, such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).

Anterior horn cells, also known as motor neurons, are a type of nerve cell located in the anterior (ventral) horn of the spinal cord's gray matter. These cells play a crucial role in initiating and regulating voluntary muscle movement by transmitting signals from the brain to the muscles via the peripheral nervous system.

Damage or degeneration of the anterior horn cells can result in various neuromuscular disorders, such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). These conditions can lead to muscle weakness, atrophy, and paralysis.

Nerve tissue proteins are specialized proteins found in the nervous system that provide structural and functional support to nerve cells, also known as neurons. These proteins include:

1. Neurofilaments: These are type IV intermediate filaments that provide structural support to neurons and help maintain their shape and size. They are composed of three subunits - NFL (light), NFM (medium), and NFH (heavy).

2. Neuronal Cytoskeletal Proteins: These include tubulins, actins, and spectrins that provide structural support to the neuronal cytoskeleton and help maintain its integrity.

3. Neurotransmitter Receptors: These are specialized proteins located on the postsynaptic membrane of neurons that bind neurotransmitters released by presynaptic neurons, triggering a response in the target cell.

4. Ion Channels: These are transmembrane proteins that regulate the flow of ions across the neuronal membrane and play a crucial role in generating and transmitting electrical signals in neurons.

5. Signaling Proteins: These include enzymes, receptors, and adaptor proteins that mediate intracellular signaling pathways involved in neuronal development, differentiation, survival, and death.

6. Adhesion Proteins: These are cell surface proteins that mediate cell-cell and cell-matrix interactions, playing a crucial role in the formation and maintenance of neural circuits.

7. Extracellular Matrix Proteins: These include proteoglycans, laminins, and collagens that provide structural support to nerve tissue and regulate neuronal migration, differentiation, and survival.

Small nuclear ribonucleoproteins (snRNPs) are a type of ribonucleoprotein (RNP) found within the nucleus of eukaryotic cells. They are composed of small nuclear RNA (snRNA) molecules and associated proteins, which are involved in various aspects of RNA processing, particularly in the modification and splicing of messenger RNA (mRNA).

The snRNPs play a crucial role in the formation of spliceosomes, large ribonucleoprotein complexes that remove introns (non-coding sequences) from pre-mRNA and join exons (coding sequences) together to form mature mRNA. Each snRNP contains a specific snRNA molecule, such as U1, U2, U4, U5, or U6, which recognizes and binds to specific sequences within the pre-mRNA during splicing. The associated proteins help stabilize the snRNP structure and facilitate its interactions with other components of the spliceosome.

In addition to their role in splicing, some snRNPs are also involved in other cellular processes, such as transcription regulation, RNA export, and DNA damage response. Dysregulation or mutations in snRNP components have been implicated in various human diseases, including cancer, neurological disorders, and autoimmune diseases.

DEAD-Box Protein 20 (DDX20) is a member of the DEAD-box protein family, which are named for the conserved amino acid sequence "Asp-Glu-Ala-Asp" within their helicase domains. These proteins are involved in various aspects of RNA metabolism, including splicing, transport, translation, and degradation.

DDX20, also known as p68 or DP103, is a DNA/RNA helicase that plays a role in transcriptional regulation, pre-mRNA processing, and RNA export. It has been implicated in several cellular processes, including cell cycle progression, differentiation, and apoptosis. DDX20 can interact with various proteins involved in transcription, such as RNA polymerase II and the basal transcription factor TFIID, as well as components of the spliceosome and other RNA-binding proteins.

Mutations or dysregulation of DDX20 have been associated with several human diseases, including cancer, neurodevelopmental disorders, and autoimmune diseases. For example, increased expression of DDX20 has been observed in various types of cancer, such as breast, lung, and ovarian cancers, and may contribute to tumor progression by promoting cell proliferation and inhibiting apoptosis. Additionally, mutations in the gene encoding DDX20 have been identified in patients with intellectual disability, epilepsy, and autism spectrum disorder.

Atrophic muscular disorders are medical conditions that involve the progressive loss of muscle mass and weakness due to the degeneration of muscle tissue. This process occurs because of a decrease in the size or number of muscle fibers, which can be caused by various factors such as nerve damage, lack of use, or underlying diseases.

There are two main types of atrophic muscular disorders: neurogenic and myopathic. Neurogenic atrophy is caused by damage to the nerves that supply the muscles, leading to muscle weakness and wasting. Examples of conditions that can cause neurogenic atrophy include motor neuron disease, spinal cord injury, and peripheral neuropathy.

Myopathic atrophy, on the other hand, is caused by primary muscle diseases that affect the muscle fibers themselves. Conditions such as muscular dystrophy, metabolic myopathies, and inflammatory myopathies can all lead to myopathic atrophy.

Symptoms of atrophic muscular disorders may include muscle weakness, wasting, cramping, spasms, and difficulty with movement and coordination. Treatment for these conditions depends on the underlying cause and may involve physical therapy, medication, or surgery. In some cases, the damage to the muscles may be irreversible, and the goal of treatment is to manage symptoms and maintain function as much as possible.

Human chromosome pair 5 consists of two rod-shaped structures present in the nucleus of human cells, which contain genetic material in the form of DNA and proteins. Each member of chromosome pair 5 is a single chromosome, and humans typically have 23 pairs of chromosomes for a total of 46 chromosomes in every cell of their body (except gametes or sex cells, which contain 23 chromosomes).

Chromosome pair 5 is one of the autosomal pairs, meaning it is not a sex chromosome. Each member of chromosome pair 5 is approximately 197 million base pairs in length and contains around 800-900 genes that provide instructions for making proteins and regulating various cellular processes.

Chromosome pair 5 is associated with several genetic disorders, including cri du chat syndrome (resulting from a deletion on the short arm of chromosome 5), Prader-Willi syndrome and Angelman syndrome (both resulting from abnormalities in gene expression on the long arm of chromosome 5).

X-linked bulbospinal neuronopathy, also known as Kennedy's disease, is a rare inherited motor neuron disorder that affects males. It is caused by a mutation in the androgen receptor (AR) gene on the X chromosome. The condition is characterized by progressive muscle weakness and atrophy, primarily affecting the bulbar muscles of the throat and tongue, as well as the limbs.

The mutation in the AR gene leads to an abnormal accumulation of the protein within nerve cells, which can ultimately result in their death. This can cause symptoms such as difficulty speaking, swallowing, and breathing, as well as muscle cramps and fasciculations (twitching). The condition typically progresses slowly over several decades.

There is no cure for X-linked bulbospinal neuronopathy, but treatments can help manage the symptoms. This may include physical therapy, speech therapy, and assistive devices to aid in breathing and swallowing.

Spinal cord injuries (SCI) refer to damage to the spinal cord that results in a loss of function, such as mobility or feeling. This injury can be caused by direct trauma to the spine or by indirect damage resulting from disease or degeneration of surrounding bones, tissues, or blood vessels. The location and severity of the injury on the spinal cord will determine which parts of the body are affected and to what extent.

The effects of SCI can range from mild sensory changes to severe paralysis, including loss of motor function, autonomic dysfunction, and possible changes in sensation, strength, and reflexes below the level of injury. These injuries are typically classified as complete or incomplete, depending on whether there is any remaining function below the level of injury.

Immediate medical attention is crucial for spinal cord injuries to prevent further damage and improve the chances of recovery. Treatment usually involves immobilization of the spine, medications to reduce swelling and pressure, surgery to stabilize the spine, and rehabilitation to help regain lost function. Despite advances in treatment, SCI can have a significant impact on a person's quality of life and ability to perform daily activities.

Exons are the coding regions of DNA that remain in the mature, processed mRNA after the removal of non-coding intronic sequences during RNA splicing. These exons contain the information necessary to encode proteins, as they specify the sequence of amino acids within a polypeptide chain. The arrangement and order of exons can vary between different genes and even between different versions of the same gene (alternative splicing), allowing for the generation of multiple protein isoforms from a single gene. This complexity in exon structure and usage significantly contributes to the diversity and functionality of the proteome.

Coiled bodies are nuclear structures found in the cells of higher organisms. They are composed of masses of DNA and RNA, as well as proteins. Coiled bodies are also known as Cajal bodies, after the Spanish histologist and neuroscientist Santiago Ramón y Cajal who first described them.

Coiled bodies are involved in various aspects of nuclear function, including the modification and processing of ribonucleoprotein (RNP) complexes, which are important for the regulation of gene expression. They also play a role in the biogenesis of telomerase, an enzyme that is responsible for maintaining the length and integrity of telomeres, the protective caps on the ends of chromosomes.

Coiled bodies are often associated with active genes and are thought to be involved in the regulation of gene expression. They have been implicated in a number of cellular processes, including transcription, splicing, and the transport of RNA. Coiled bodies are dynamic structures that can change in size and number in response to various stimuli, such as changes in the cell cycle or exposure to certain drugs.

It is worth noting that while coiled bodies have been well-studied, there is still much that is not known about their precise functions and how they contribute to normal cellular processes and disease.

SnRNP (small nuclear ribonucleoprotein) core proteins are a group of proteins that are associated with small nuclear RNAs (snRNAs) to form small nuclear ribonucleoprotein particles. These particles play crucial roles in various aspects of RNA processing, such as splicing, 3' end formation, and degradation.

The snRNP core proteins include seven Sm proteins (B, D1, D2, D3, E, F, and G) that form a heptameric ring-like structure called the Sm core, which binds to a conserved sequence motif in the snRNAs called the Sm site. In addition to the Sm proteins, there are also other core proteins such as Sm like (L) proteins and various other protein factors that associate with specific snRNP particles.

Together, these snRNP core proteins help to stabilize the snRNA, facilitate its assembly into functional ribonucleoprotein complexes, and participate in the recognition and processing of target RNAs during post-transcriptional regulation.

Motor Neuron Disease (MND) is a progressive neurodegenerative disorder that affects the motor neurons, which are nerve cells in the brain and spinal cord responsible for controlling voluntary muscles involved in movement, speaking, breathing, and swallowing. As the motor neurons degenerate and die, they stop sending signals to the muscles, causing them to weaken, waste away (atrophy), and eventually lead to paralysis.

There are several types of MND, including:

1. Amyotrophic Lateral Sclerosis (ALS): Also known as Lou Gehrig's disease, this is the most common form of MND. It affects both upper and lower motor neurons, causing muscle weakness, stiffness, twitching, and atrophy throughout the body.
2. Progressive Bulbar Palsy (PBP): This type primarily affects the bulbar muscles in the brainstem, which control speech, swallowing, and chewing. Patients with PBP experience difficulties with speaking, slurred speech, and problems swallowing and may also have weak facial muscles and limb weakness.
3. Primary Lateral Sclerosis (PLS): This form of MND affects only the upper motor neurons, causing muscle stiffness, spasticity, and weakness, primarily in the legs. PLS progresses more slowly than ALS, and patients usually maintain their ability to speak and swallow for a longer period.
4. Progressive Muscular Atrophy (PMA): This type of MND affects only the lower motor neurons, causing muscle wasting, weakness, and fasciculations (muscle twitches). PMA progresses more slowly than ALS but can still be severely disabling over time.
5. Spinal Muscular Atrophy (SMA): This is a genetic form of MND that typically presents in infancy or childhood, although adult-onset forms exist. SMA affects the lower motor neurons in the spinal cord, causing muscle weakness and atrophy, primarily in the legs and trunk.

The exact cause of Motor Neuron Disease is not fully understood, but it is believed to involve a combination of genetic, environmental, and lifestyle factors. There is currently no cure for MND, and treatment focuses on managing symptoms, maintaining quality of life, and slowing disease progression through various therapies and medications.

Spinal cord diseases refer to a group of conditions that affect the spinal cord, which is a part of the central nervous system responsible for transmitting messages between the brain and the rest of the body. These diseases can cause damage to the spinal cord, leading to various symptoms such as muscle weakness, numbness, pain, bladder and bowel dysfunction, and difficulty with movement and coordination.

Spinal cord diseases can be congenital or acquired, and they can result from a variety of causes, including infections, injuries, tumors, degenerative conditions, autoimmune disorders, and genetic factors. Some examples of spinal cord diseases include multiple sclerosis, spina bifida, spinal cord injury, herniated discs, spinal stenosis, and motor neuron diseases such as amyotrophic lateral sclerosis (ALS).

The treatment for spinal cord diseases varies depending on the underlying cause and severity of the condition. Treatment options may include medication, physical therapy, surgery, and rehabilitation. In some cases, the damage to the spinal cord may be irreversible, leading to permanent disability or paralysis.

Animal disease models are specialized animals, typically rodents such as mice or rats, that have been genetically engineered or exposed to certain conditions to develop symptoms and physiological changes similar to those seen in human diseases. These models are used in medical research to study the pathophysiology of diseases, identify potential therapeutic targets, test drug efficacy and safety, and understand disease mechanisms.

The genetic modifications can include knockout or knock-in mutations, transgenic expression of specific genes, or RNA interference techniques. The animals may also be exposed to environmental factors such as chemicals, radiation, or infectious agents to induce the disease state.

Examples of animal disease models include:

1. Mouse models of cancer: Genetically engineered mice that develop various types of tumors, allowing researchers to study cancer initiation, progression, and metastasis.
2. Alzheimer's disease models: Transgenic mice expressing mutant human genes associated with Alzheimer's disease, which exhibit amyloid plaque formation and cognitive decline.
3. Diabetes models: Obese and diabetic mouse strains like the NOD (non-obese diabetic) or db/db mice, used to study the development of type 1 and type 2 diabetes, respectively.
4. Cardiovascular disease models: Atherosclerosis-prone mice, such as ApoE-deficient or LDLR-deficient mice, that develop plaque buildup in their arteries when fed a high-fat diet.
5. Inflammatory bowel disease models: Mice with genetic mutations affecting intestinal barrier function and immune response, such as IL-10 knockout or SAMP1/YitFc mice, which develop colitis.

Animal disease models are essential tools in preclinical research, but it is important to recognize their limitations. Differences between species can affect the translatability of results from animal studies to human patients. Therefore, researchers must carefully consider the choice of model and interpret findings cautiously when applying them to human diseases.

I must clarify that the term "pedigree" is not typically used in medical definitions. Instead, it is often employed in genetics and breeding, where it refers to the recorded ancestry of an individual or a family, tracing the inheritance of specific traits or diseases. In human genetics, a pedigree can help illustrate the pattern of genetic inheritance in families over multiple generations. However, it is not a medical term with a specific clinical definition.

Heterozygote detection is a method used in genetics to identify individuals who carry one normal and one mutated copy of a gene. These individuals are known as heterozygotes and they do not typically show symptoms of the genetic disorder associated with the mutation, but they can pass the mutated gene on to their offspring, who may then be affected.

Heterozygote detection is often used in genetic counseling and screening programs for recessive disorders such as cystic fibrosis or sickle cell anemia. By identifying heterozygotes, individuals can be informed of their carrier status and the potential risks to their offspring. This information can help them make informed decisions about family planning and reproductive options.

Various methods can be used for heterozygote detection, including polymerase chain reaction (PCR) based tests, DNA sequencing, and genetic linkage analysis. The choice of method depends on the specific gene or mutation being tested, as well as the availability and cost of the testing technology.

Glycine-tRNA ligase, also known as glycyl-tRNA synthetase, is an enzyme that plays a crucial role in protein synthesis. Its primary function is to catalyze the reaction between the amino acid glycine and its corresponding transfer RNA (tRNA) molecule. This reaction forms a covalent bond between glycine and tRNA, creating a charged tRNA molecule that can then participate in protein synthesis on the ribosome.

The systematic name for this enzyme is "glycyl-tRNA ligase (AMP-forming)" and it belongs to the class II aminoacyl-tRNA synthetases. It requires ATP as a cofactor to activate the glycine molecule before forming the ester bond with tRNA. Defects in this enzyme have been associated with certain neurological disorders, such as Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V.

Gene deletion is a type of mutation where a segment of DNA, containing one or more genes, is permanently lost or removed from a chromosome. This can occur due to various genetic mechanisms such as homologous recombination, non-homologous end joining, or other types of genomic rearrangements.

The deletion of a gene can have varying effects on the organism, depending on the function of the deleted gene and its importance for normal physiological processes. If the deleted gene is essential for survival, the deletion may result in embryonic lethality or developmental abnormalities. However, if the gene is non-essential or has redundant functions, the deletion may not have any noticeable effects on the organism's phenotype.

Gene deletions can also be used as a tool in genetic research to study the function of specific genes and their role in various biological processes. For example, researchers may use gene deletion techniques to create genetically modified animal models to investigate the impact of gene deletion on disease progression or development.

A phenotype is the physical or biochemical expression of an organism's genes, or the observable traits and characteristics resulting from the interaction of its genetic constitution (genotype) with environmental factors. These characteristics can include appearance, development, behavior, and resistance to disease, among others. Phenotypes can vary widely, even among individuals with identical genotypes, due to differences in environmental influences, gene expression, and genetic interactions.

Neuromuscular junction diseases are a group of disorders that affect the functioning of the neuromuscular junction, which is the site where nerve impulses are transmitted to muscles. These diseases are characterized by muscle weakness and fatigue, and can be caused by various factors such as autoimmune disorders, genetic mutations, or toxins.

Examples of neuromuscular junction diseases include myasthenia gravis, Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), and botulism. Myasthenia gravis is an autoimmune disorder that causes the immune system to attack the receptors in the neuromuscular junction, leading to muscle weakness and fatigue. LEMS is a rare autoimmune disorder that affects the nerve endings at the neuromuscular junction, causing muscle weakness and decreased reflexes.

Congenital myasthenic syndromes are genetic disorders that affect the functioning of the neuromuscular junction from birth, leading to muscle weakness and fatigue. Botulism is a rare but serious condition caused by the ingestion of botulinum toxin, which can lead to paralysis of the muscles due to interference with nerve impulse transmission at the neuromuscular junction.

Treatment for neuromuscular junction diseases may include medications such as cholinesterase inhibitors, immunosuppressive drugs, or plasma exchange therapy, depending on the specific diagnosis and severity of the condition.

RNA splicing is a post-transcriptional modification process in which the non-coding sequences (introns) are removed and the coding sequences (exons) are joined together in a messenger RNA (mRNA) molecule. This results in a continuous mRNA sequence that can be translated into a single protein. Alternative splicing, where different combinations of exons are included or excluded, allows for the creation of multiple proteins from a single gene.

A homozygote is an individual who has inherited the same allele (version of a gene) from both parents and therefore possesses two identical copies of that allele at a specific genetic locus. This can result in either having two dominant alleles (homozygous dominant) or two recessive alleles (homozygous recessive). In contrast, a heterozygote has inherited different alleles from each parent for a particular gene.

The term "homozygote" is used in genetics to describe the genetic makeup of an individual at a specific locus on their chromosomes. Homozygosity can play a significant role in determining an individual's phenotype (observable traits), as having two identical alleles can strengthen the expression of certain characteristics compared to having just one dominant and one recessive allele.

Transgenic mice are genetically modified rodents that have incorporated foreign DNA (exogenous DNA) into their own genome. This is typically done through the use of recombinant DNA technology, where a specific gene or genetic sequence of interest is isolated and then introduced into the mouse embryo. The resulting transgenic mice can then express the protein encoded by the foreign gene, allowing researchers to study its function in a living organism.

The process of creating transgenic mice usually involves microinjecting the exogenous DNA into the pronucleus of a fertilized egg, which is then implanted into a surrogate mother. The offspring that result from this procedure are screened for the presence of the foreign DNA, and those that carry the desired genetic modification are used to establish a transgenic mouse line.

Transgenic mice have been widely used in biomedical research to model human diseases, study gene function, and test new therapies. They provide a valuable tool for understanding complex biological processes and developing new treatments for a variety of medical conditions.

Skeletal muscle, also known as striated or voluntary muscle, is a type of muscle that is attached to bones by tendons or aponeuroses and functions to produce movements and support the posture of the body. It is composed of long, multinucleated fibers that are arranged in parallel bundles and are characterized by alternating light and dark bands, giving them a striped appearance under a microscope. Skeletal muscle is under voluntary control, meaning that it is consciously activated through signals from the nervous system. It is responsible for activities such as walking, running, jumping, and lifting objects.

Optic atrophy is a medical term that refers to the degeneration and shrinkage (atrophy) of the optic nerve, which transmits visual information from the eye to the brain. This condition can result in various vision abnormalities, including loss of visual acuity, color vision deficiencies, and peripheral vision loss.

Optic atrophy can occur due to a variety of causes, such as:

* Traumatic injuries to the eye or optic nerve
* Glaucoma
* Optic neuritis (inflammation of the optic nerve)
* Ischemic optic neuropathy (reduced blood flow to the optic nerve)
* Compression or swelling of the optic nerve
* Hereditary or congenital conditions affecting the optic nerve
* Toxins and certain medications that can damage the optic nerve.

The diagnosis of optic atrophy typically involves a comprehensive eye examination, including visual acuity testing, refraction assessment, slit-lamp examination, and dilated funduscopic examination to evaluate the health of the optic nerve. In some cases, additional diagnostic tests such as visual field testing, optical coherence tomography (OCT), or magnetic resonance imaging (MRI) may be necessary to confirm the diagnosis and determine the underlying cause.

There is no specific treatment for optic atrophy, but addressing the underlying cause can help prevent further damage to the optic nerve. In some cases, vision rehabilitation may be recommended to help patients adapt to their visual impairment.

Arthrogryposis is a medical term that describes a condition characterized by the presence of multiple joint contractures at birth. A contracture occurs when the range of motion in a joint is limited, making it difficult or impossible to move the joint through its full range of motion. In arthrogryposis, these contractures are present in two or more areas of the body.

The term "arthrogryposis" comes from two Greek words: "arthro," meaning joint, and "gyros," meaning curved or bent. Therefore, arthrogryposis literally means "curving of the joints."

There are many different types of arthrogryposis, each with its own specific set of symptoms and causes. However, in general, arthrogryposis is caused by decreased fetal movement during pregnancy, which can be due to a variety of factors such as genetic mutations, nervous system abnormalities, or environmental factors that restrict fetal movement.

Treatment for arthrogryposis typically involves a combination of physical therapy, bracing, and surgery to help improve joint mobility and function. The prognosis for individuals with arthrogryposis varies depending on the severity and type of contractures present, as well as the underlying cause of the condition.

The neuromuscular junction (NMJ) is the specialized synapse or chemical communication point, where the motor neuron's nerve terminal (presynaptic element) meets the muscle fiber's motor end plate (postsynaptic element). This junction plays a crucial role in controlling muscle contraction and relaxation.

At the NMJ, the neurotransmitter acetylcholine is released from the presynaptic nerve terminal into the synaptic cleft, following an action potential. Acetylcholine then binds to nicotinic acetylcholine receptors on the postsynaptic membrane of the muscle fiber, leading to the generation of an end-plate potential. If sufficient end-plate potentials are generated and summate, they will trigger an action potential in the muscle fiber, ultimately causing muscle contraction.

Dysfunction at the neuromuscular junction can result in various neuromuscular disorders, such as myasthenia gravis, where autoantibodies attack acetylcholine receptors, leading to muscle weakness and fatigue.

Gene dosage, in genetic terms, refers to the number of copies of a particular gene present in an organism's genome. Each gene usually has two copies (alleles) in diploid organisms, one inherited from each parent. An increase or decrease in the number of copies of a specific gene can lead to changes in the amount of protein it encodes, which can subsequently affect various biological processes and phenotypic traits.

For example, gene dosage imbalances have been associated with several genetic disorders, such as Down syndrome (trisomy 21), where an individual has three copies of chromosome 21 instead of the typical two copies, leading to developmental delays and intellectual disabilities. Similarly, in certain cases of cancer, gene amplification (an increase in the number of copies of a particular gene) can result in overexpression of oncogenes, contributing to tumor growth and progression.

An axon is a long, slender extension of a neuron (a type of nerve cell) that conducts electrical impulses (nerve impulses) away from the cell body to target cells, such as other neurons or muscle cells. Axons can vary in length from a few micrometers to over a meter long and are typically surrounded by a myelin sheath, which helps to insulate and protect the axon and allows for faster transmission of nerve impulses.

Axons play a critical role in the functioning of the nervous system, as they provide the means by which neurons communicate with one another and with other cells in the body. Damage to axons can result in serious neurological problems, such as those seen in spinal cord injuries or neurodegenerative diseases like multiple sclerosis.

A contracture, in a medical context, refers to the abnormal shortening and hardening of muscles, tendons, or other tissue, which can result in limited mobility and deformity of joints. This condition can occur due to various reasons such as injury, prolonged immobilization, scarring, neurological disorders, or genetic conditions.

Contractures can cause significant impairment in daily activities and quality of life, making it difficult for individuals to perform routine tasks like dressing, bathing, or walking. Treatment options may include physical therapy, splinting, casting, medications, surgery, or a combination of these approaches, depending on the severity and underlying cause of the contracture.

A mutation is a permanent change in the DNA sequence of an organism's genome. Mutations can occur spontaneously or be caused by environmental factors such as exposure to radiation, chemicals, or viruses. They may have various effects on the organism, ranging from benign to harmful, depending on where they occur and whether they alter the function of essential proteins. In some cases, mutations can increase an individual's susceptibility to certain diseases or disorders, while in others, they may confer a survival advantage. Mutations are the driving force behind evolution, as they introduce new genetic variability into populations, which can then be acted upon by natural selection.

Electromyography (EMG) is a medical diagnostic procedure that measures the electrical activity of skeletal muscles during contraction and at rest. It involves inserting a thin needle electrode into the muscle to record the electrical signals generated by the muscle fibers. These signals are then displayed on an oscilloscope and may be heard through a speaker.

EMG can help diagnose various neuromuscular disorders, such as muscle weakness, numbness, or pain, and can distinguish between muscle and nerve disorders. It is often used in conjunction with other diagnostic tests, such as nerve conduction studies, to provide a comprehensive evaluation of the nervous system.

EMG is typically performed by a neurologist or a physiatrist, and the procedure may cause some discomfort or pain, although this is usually minimal. The results of an EMG can help guide treatment decisions and monitor the progression of neuromuscular conditions over time.

Neuromuscular diseases are a group of disorders that involve the peripheral nervous system, which includes the nerves and muscles outside of the brain and spinal cord. These conditions can affect both children and adults, and they can be inherited or acquired. Neuromuscular diseases can cause a wide range of symptoms, including muscle weakness, numbness, tingling, pain, cramping, and twitching. Some common examples of neuromuscular diseases include muscular dystrophy, amyotrophic lateral sclerosis (ALS), peripheral neuropathy, and myasthenia gravis. The specific symptoms and severity of these conditions can vary widely depending on the underlying cause and the specific muscles and nerves that are affected. Treatment for neuromuscular diseases may include medications, physical therapy, assistive devices, or surgery, depending on the individual case.

Nerve degeneration, also known as neurodegeneration, is the progressive loss of structure and function of neurons, which can lead to cognitive decline, motor impairment, and various other symptoms. This process occurs due to a variety of factors, including genetics, environmental influences, and aging. It is a key feature in several neurological disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. The degeneration can affect any part of the nervous system, leading to different symptoms depending on the location and extent of the damage.

Recessive genes refer to the alleles (versions of a gene) that will only be expressed when an individual has two copies of that particular allele, one inherited from each parent. If an individual inherits one recessive allele and one dominant allele for a particular gene, the dominant allele will be expressed and the recessive allele will have no effect on the individual's phenotype (observable traits).

Recessive genes can still play a role in determining an individual's genetic makeup and can be passed down through generations even if they are not expressed. If two carriers of a recessive gene have children, there is a 25% chance that their offspring will inherit two copies of the recessive allele and exhibit the associated recessive trait.

Examples of genetic disorders caused by recessive genes include cystic fibrosis, sickle cell anemia, and albinism.

Analytical chemistry is a branch of chemistry that focuses on the identification and quantification of chemical components within a sample. This field involves developing and using various analytical techniques and methods to determine the presence, concentration, structure, and purity of different chemicals or compounds in a mixture.

Some common analytical techniques include:

1. Spectroscopy: Using light or other electromagnetic radiation to study the interaction between matter and energy, providing information about the composition, structure, and properties of a sample. Examples include UV-Vis, IR, NMR, and mass spectrometry.
2. Chromatography: A separation technique that separates components in a mixture based on their interactions with a mobile phase (gas or liquid) and a stationary phase (solid or liquid). Common methods include gas chromatography (GC), liquid chromatography (LC), and thin-layer chromatography (TLC).
3. Electrochemical analysis: Measuring the electrical properties of a sample, such as potential, current, or resistance, to determine its composition or concentration. Examples include potentiometry, voltammetry, and conductometry.
4. Thermal analysis: Examining the physical and chemical changes that occur in a sample when it is heated or cooled, providing information about its composition, structure, and properties. Techniques include differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and dynamic mechanical analysis (DMA).
5. Spectrometry: Measuring the intensity of light dispersed by a sample as a function of wavelength or frequency to determine its composition, structure, or properties. Examples include atomic absorption spectroscopy (AAS), inductively coupled plasma mass spectrometry (ICP-MS), and X-ray fluorescence spectrometry (XRF).

Analytical chemists often work in various industries, such as pharmaceuticals, food, environmental testing, and forensics, to ensure product quality, safety, and compliance with regulations. They may also contribute to research and development efforts by developing new analytical methods or improving existing ones.

Charcot-Marie-Tooth disease (CMT) is a group of inherited disorders that cause nerve damage, primarily affecting the peripheral nerves. These are the nerves that transmit signals between the brain and spinal cord to the rest of the body. CMT affects both motor and sensory nerves, leading to muscle weakness and atrophy, as well as numbness or tingling in the hands and feet.

The disease is named after the three physicians who first described it: Jean-Martin Charcot, Pierre Marie, and Howard Henry Tooth. CMT is characterized by its progressive nature, meaning symptoms typically worsen over time, although the rate of progression can vary significantly among individuals.

There are several types of CMT, classified based on their genetic causes and patterns of inheritance. The two most common forms are CMT1 and CMT2:

1. CMT1: This form is caused by mutations in the genes responsible for the myelin sheath, which insulates peripheral nerves and allows for efficient signal transmission. As a result, demyelination occurs, slowing down nerve impulses and causing muscle weakness, particularly in the lower limbs. Symptoms usually begin in childhood or adolescence and include foot drop, high arches, and hammertoes.
2. CMT2: This form is caused by mutations in the genes responsible for the axons, the nerve fibers that transmit signals within peripheral nerves. As a result, axonal degeneration occurs, leading to muscle weakness and atrophy. Symptoms usually begin in early adulthood and progress more slowly than CMT1. They primarily affect the lower limbs but can also involve the hands and arms.

Diagnosis of CMT typically involves a combination of clinical evaluation, family history, nerve conduction studies, and genetic testing. While there is no cure for CMT, treatment focuses on managing symptoms and maintaining mobility and function through physical therapy, bracing, orthopedic surgery, and pain management.

Prenatal diagnosis is the medical testing of fetuses, embryos, or pregnant women to detect the presence or absence of certain genetic disorders or birth defects. These tests can be performed through various methods such as chorionic villus sampling (CVS), amniocentesis, or ultrasound. The goal of prenatal diagnosis is to provide early information about the health of the fetus so that parents and healthcare providers can make informed decisions about pregnancy management and newborn care. It allows for early intervention, treatment, or planning for the child's needs after birth.

A fasciculation is an involuntary muscle contraction and relaxation that occurs randomly and spontaneously, causing a visible twitching of the muscle. Fasciculations can occur in any skeletal muscle of the body and are often described as feeling like a "mini-charley horse." They are generally harmless and can occur in people without any underlying neurological conditions. However, they can also be a symptom of certain neuromuscular disorders, such as amyotrophic lateral sclerosis (ALS) or motor neuron disease. In these cases, fasciculations are often accompanied by other symptoms, such as muscle weakness, atrophy, and cramping. If you are experiencing persistent or frequent fasciculations, it is important to consult with a healthcare professional for further evaluation and diagnosis.

Dominant genes refer to the alleles (versions of a gene) that are fully expressed in an individual's phenotype, even if only one copy of the gene is present. In dominant inheritance patterns, an individual needs only to receive one dominant allele from either parent to express the associated trait. This is in contrast to recessive genes, where both copies of the gene must be the recessive allele for the trait to be expressed. Dominant genes are represented by uppercase letters (e.g., 'A') and recessive genes by lowercase letters (e.g., 'a'). If an individual inherits one dominant allele (A) from either parent, they will express the dominant trait (A).

Vocal cord paralysis is a medical condition characterized by the inability of one or both vocal cords to move or function properly due to nerve damage or disruption. The vocal cords are two bands of muscle located in the larynx (voice box) that vibrate to produce sound during speech, singing, and breathing. When the nerves that control the vocal cord movements are damaged or not functioning correctly, the vocal cords may become paralyzed or weakened, leading to voice changes, breathing difficulties, and other symptoms.

The causes of vocal cord paralysis can vary, including neurological disorders, trauma, tumors, surgery, or infections. The diagnosis typically involves a physical examination, including a laryngoscopy, to assess the movement and function of the vocal cords. Treatment options may include voice therapy, surgical procedures, or other interventions to improve voice quality and breathing functions.

Spinal injections, also known as epidural injections or intrathecal injections, are medical procedures involving the injection of medications directly into the spinal canal. The medication is usually delivered into the space surrounding the spinal cord (the epidural space) or into the cerebrospinal fluid that surrounds and protects the spinal cord (the subarachnoid space).

The medications used in spinal injections can include local anesthetics, steroids, opioids, or a combination of these. The purpose of spinal injections is to provide diagnostic information, therapeutic relief, or both. They are commonly used to treat various conditions affecting the spine, such as radicular pain (pain that radiates down the arms or legs), disc herniation, spinal stenosis, and degenerative disc disease.

Spinal injections can be administered using different techniques, including fluoroscopy-guided injections, computed tomography (CT) scan-guided injections, or with the help of a nerve stimulator. These techniques ensure accurate placement of the medication and minimize the risk of complications.

It is essential to consult a healthcare professional for specific information regarding spinal injections and their potential benefits and risks.

Genetic linkage is the phenomenon where two or more genetic loci (locations on a chromosome) tend to be inherited together because they are close to each other on the same chromosome. This occurs during the process of sexual reproduction, where homologous chromosomes pair up and exchange genetic material through a process called crossing over.

The closer two loci are to each other on a chromosome, the lower the probability that they will be separated by a crossover event. As a result, they are more likely to be inherited together and are said to be linked. The degree of linkage between two loci can be measured by their recombination frequency, which is the percentage of meiotic events in which a crossover occurs between them.

Linkage analysis is an important tool in genetic research, as it allows researchers to identify and map genes that are associated with specific traits or diseases. By analyzing patterns of linkage between markers (identifiable DNA sequences) and phenotypes (observable traits), researchers can infer the location of genes that contribute to those traits or diseases on chromosomes.

Spinal nerve roots are the initial parts of spinal nerves that emerge from the spinal cord through the intervertebral foramen, which are small openings between each vertebra in the spine. These nerve roots carry motor, sensory, and autonomic fibers to and from specific regions of the body. There are 31 pairs of spinal nerve roots in total, with 8 cervical, 12 thoracic, 5 lumbar, 5 sacral, and 1 coccygeal pair. Each root has a dorsal (posterior) and ventral (anterior) ramus that branch off to form the peripheral nervous system. Irritation or compression of these nerve roots can result in pain, numbness, weakness, or loss of reflexes in the affected area.

Genetic counseling is a process of communication and education between a healthcare professional and an individual or family, aimed at understanding, adapting to, and managing the medical, psychological, and familial implications of genetic contributions to disease. This includes providing information about the risk of inherited conditions, explaining the implications of test results, discussing reproductive options, and offering support and resources for coping with a genetic condition. Genetic counselors are trained healthcare professionals who specialize in helping people understand genetic information and its impact on their health and lives.

A spliceosome is a complex of ribonucleoprotein (RNP) particles found in the nucleus of eukaryotic cells that removes introns (non-coding sequences) from precursor messenger RNA (pre-mRNA) and joins exons (coding sequences) together to form mature mRNA. This process is called splicing, which is an essential step in gene expression and protein synthesis. Spliceosomes are composed of five small nuclear ribonucleoprotein particles (snRNPs), known as U1, U2, U4/U6, and U5 snRNPs, and numerous proteins. The assembly of spliceosomes and the splicing reaction are highly regulated and can be influenced by various factors, including cis-acting elements in pre-mRNA and trans-acting factors such as serine/arginine-rich (SR) proteins.

Muscle weakness is a condition in which muscles cannot develop the expected level of physical force or power. This results in reduced muscle function and can be caused by various factors, including nerve damage, muscle diseases, or hormonal imbalances. Muscle weakness may manifest as difficulty lifting objects, maintaining posture, or performing daily activities. It is essential to consult a healthcare professional for proper diagnosis and treatment of muscle weakness.

Alternative splicing is a process in molecular biology that occurs during the post-transcriptional modification of pre-messenger RNA (pre-mRNA) molecules. It involves the removal of non-coding sequences, known as introns, and the joining together of coding sequences, or exons, to form a mature messenger RNA (mRNA) molecule that can be translated into a protein.

In alternative splicing, different combinations of exons are selected and joined together to create multiple distinct mRNA transcripts from a single pre-mRNA template. This process increases the diversity of proteins that can be produced from a limited number of genes, allowing for greater functional complexity in organisms.

Alternative splicing is regulated by various cis-acting elements and trans-acting factors that bind to specific sequences in the pre-mRNA molecule and influence which exons are included or excluded during splicing. Abnormal alternative splicing has been implicated in several human diseases, including cancer, neurological disorders, and cardiovascular disease.

Respiratory paralysis is a condition characterized by the inability to breathe effectively due to the failure or weakness of the muscles involved in respiration. This can include the diaphragm, intercostal muscles, and other accessory muscles.

In medical terms, it's often associated with conditions that affect the neuromuscular junction, such as botulism, myasthenia gravis, or spinal cord injuries. It can also occur as a complication of general anesthesia, sedative drugs, or certain types of poisoning.

Respiratory paralysis is a serious condition that requires immediate medical attention, as it can lead to lack of oxygen (hypoxia) and buildup of carbon dioxide (hypercapnia) in the body, which can be life-threatening if not treated promptly.

Neural conduction is the process by which electrical signals, known as action potentials, are transmitted along the axon of a neuron (nerve cell) to transmit information between different parts of the nervous system. This electrical impulse is generated by the movement of ions across the neuronal membrane, and it propagates down the length of the axon until it reaches the synapse, where it can then stimulate the release of neurotransmitters to communicate with other neurons or target cells. The speed of neural conduction can vary depending on factors such as the diameter of the axon, the presence of myelin sheaths (which act as insulation and allow for faster conduction), and the temperature of the environment.

Valproic acid is a medication that is primarily used as an anticonvulsant, which means it is used to treat seizure disorders. It works by increasing the amount of gamma-aminobutyric acid (GABA) in the brain, a neurotransmitter that helps to reduce abnormal electrical activity in the brain. In addition to its use as an anticonvulsant, valproic acid may also be used to treat migraines and bipolar disorder. It is available in various forms, including tablets, capsules, and liquid solutions, and is usually taken by mouth. As with any medication, valproic acid can have side effects, and it is important for patients to be aware of these and to discuss them with their healthcare provider.

Spinal nerves are the bundles of nerve fibers that transmit signals between the spinal cord and the rest of the body. There are 31 pairs of spinal nerves in the human body, which can be divided into five regions: 8 cervical, 12 thoracic, 5 lumbar, 5 sacral, and 1 coccygeal. Each spinal nerve carries both sensory information (such as touch, temperature, and pain) from the periphery to the spinal cord, and motor information (such as muscle control) from the spinal cord to the muscles and other structures in the body. Spinal nerves also contain autonomic fibers that regulate involuntary functions such as heart rate, digestion, and blood pressure.

Genetic testing is a type of medical test that identifies changes in chromosomes, genes, or proteins. The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a person's chance of developing or passing on a genetic disorder. Genetic tests are performed on a sample of blood, hair, skin, amniotic fluid (the fluid that surrounds a fetus during pregnancy), or other tissue. For example, a physician may recommend genetic testing to help diagnose a genetic condition, confirm the presence of a gene mutation known to increase the risk of developing certain cancers, or determine the chance for a couple to have a child with a genetic disorder.

There are several types of genetic tests, including:

* Diagnostic testing: This type of test is used to identify or confirm a suspected genetic condition in an individual. It may be performed before birth (prenatal testing) or at any time during a person's life.
* Predictive testing: This type of test is used to determine the likelihood that a person will develop a genetic disorder. It is typically offered to individuals who have a family history of a genetic condition but do not show any symptoms themselves.
* Carrier testing: This type of test is used to determine whether a person carries a gene mutation for a genetic disorder. It is often offered to couples who are planning to have children and have a family history of a genetic condition or belong to a population that has an increased risk of certain genetic disorders.
* Preimplantation genetic testing: This type of test is used in conjunction with in vitro fertilization (IVF) to identify genetic changes in embryos before they are implanted in the uterus. It can help couples who have a family history of a genetic disorder or who are at risk of having a child with a genetic condition to conceive a child who is free of the genetic change in question.
* Pharmacogenetic testing: This type of test is used to determine how an individual's genes may affect their response to certain medications. It can help healthcare providers choose the most effective medication and dosage for a patient, reducing the risk of adverse drug reactions.

It is important to note that genetic testing should be performed under the guidance of a qualified healthcare professional who can interpret the results and provide appropriate counseling and support.

Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder that affects multiple systems in the body. It is characterized by a combination of symptoms including Parkinsonism (such as stiffness, slowness of movement, and tremors), cerebellar ataxia (lack of muscle coordination), autonomic dysfunction (problems with the autonomic nervous system which controls involuntary actions like heart rate, blood pressure, sweating, and digestion), and pyramidal signs (abnormalities in the corticospinal tracts that control voluntary movements).

The disorder is caused by the degeneration of nerve cells in various parts of the brain and spinal cord, leading to a loss of function in these areas. The exact cause of MSA is unknown, but it is thought to involve a combination of genetic and environmental factors. There is currently no cure for MSA, and treatment is focused on managing symptoms and improving quality of life.

Spinal anesthesia is a type of regional anesthesia that involves injecting local anesthetic medication into the cerebrospinal fluid in the subarachnoid space, which is the space surrounding the spinal cord. This procedure is typically performed by introducing a needle into the lower back, between the vertebrae, to reach the subarachnoid space.

Once the local anesthetic is introduced into this space, it spreads to block nerve impulses from the corresponding levels of the spine, resulting in numbness and loss of sensation in specific areas of the body below the injection site. The extent and level of anesthesia depend on the amount and type of medication used, as well as the patient's individual response.

Spinal anesthesia is often used for surgeries involving the lower abdomen, pelvis, or lower extremities, such as cesarean sections, hernia repairs, hip replacements, and knee arthroscopies. It can also be utilized for procedures like epidural steroid injections to manage chronic pain conditions affecting the spine and lower limbs.

While spinal anesthesia provides effective pain relief during and after surgery, it may cause side effects such as low blood pressure, headache, or difficulty urinating. These potential complications should be discussed with the healthcare provider before deciding on this type of anesthesia.

Aclarubicin is an anthracycline antibiotic used in cancer chemotherapy. It works by interfering with the DNA in cancer cells, preventing them from dividing and growing. Aclarubicin is often used to treat acute leukemias, lymphomas, and solid tumors.

Like other anthracyclines, aclarubicin can cause significant side effects, including damage to the heart muscle, suppression of bone marrow function, and hair loss. It may also cause nausea, vomiting, and mouth sores. Aclarubicin is usually given by injection into a vein.

It's important to note that the use of aclarubicin should be under the supervision of a healthcare professional, as its administration requires careful monitoring due to potential toxicities.

A newborn infant is a baby who is within the first 28 days of life. This period is also referred to as the neonatal period. Newborns require specialized care and attention due to their immature bodily systems and increased vulnerability to various health issues. They are closely monitored for signs of well-being, growth, and development during this critical time.

"Motor activity" is a general term used in the field of medicine and neuroscience to refer to any kind of physical movement or action that is generated by the body's motor system. The motor system includes the brain, spinal cord, nerves, and muscles that work together to produce movements such as walking, talking, reaching for an object, or even subtle actions like moving your eyes.

Motor activity can be voluntary, meaning it is initiated intentionally by the individual, or involuntary, meaning it is triggered automatically by the nervous system without conscious control. Examples of voluntary motor activity include deliberately lifting your arm or kicking a ball, while examples of involuntary motor activity include heartbeat, digestion, and reflex actions like jerking your hand away from a hot stove.

Abnormalities in motor activity can be a sign of neurological or muscular disorders, such as Parkinson's disease, cerebral palsy, or multiple sclerosis. Assessment of motor activity is often used in the diagnosis and treatment of these conditions.

Fibroblasts are specialized cells that play a critical role in the body's immune response and wound healing process. They are responsible for producing and maintaining the extracellular matrix (ECM), which is the non-cellular component present within all tissues and organs, providing structural support and biochemical signals for surrounding cells.

Fibroblasts produce various ECM proteins such as collagens, elastin, fibronectin, and laminins, forming a complex network of fibers that give tissues their strength and flexibility. They also help in the regulation of tissue homeostasis by controlling the turnover of ECM components through the process of remodeling.

In response to injury or infection, fibroblasts become activated and start to proliferate rapidly, migrating towards the site of damage. Here, they participate in the inflammatory response, releasing cytokines and chemokines that attract immune cells to the area. Additionally, they deposit new ECM components to help repair the damaged tissue and restore its functionality.

Dysregulation of fibroblast activity has been implicated in several pathological conditions, including fibrosis (excessive scarring), cancer (where they can contribute to tumor growth and progression), and autoimmune diseases (such as rheumatoid arthritis).

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord responsible for controlling voluntary muscle movements, such as speaking, walking, breathing, and swallowing. The condition is characterized by the degeneration of motor neurons in the brain (upper motor neurons) and spinal cord (lower motor neurons), leading to their death.

The term "amyotrophic" comes from the Greek words "a" meaning no or negative, "myo" referring to muscle, and "trophic" relating to nutrition. When a motor neuron degenerates and can no longer send impulses to the muscle, the muscle becomes weak and eventually atrophies due to lack of use.

The term "lateral sclerosis" refers to the hardening or scarring (sclerosis) of the lateral columns of the spinal cord, which are primarily composed of nerve fibers that carry information from the brain to the muscles.

ALS is often called Lou Gehrig's disease, named after the famous American baseball player who was diagnosed with the condition in 1939. The exact cause of ALS remains unknown, but it is believed to involve a combination of genetic and environmental factors. There is currently no cure for ALS, and treatment primarily focuses on managing symptoms and maintaining quality of life.

The progression of ALS varies from person to person, with some individuals experiencing rapid decline over just a few years, while others may have a more slow-progressing form of the disease that lasts several decades. The majority of people with ALS die from respiratory failure within 3 to 5 years after the onset of symptoms. However, approximately 10% of those affected live for 10 or more years following diagnosis.

Androgen receptors (ARs) are a type of nuclear receptor protein that are expressed in various tissues throughout the body. They play a critical role in the development and maintenance of male sexual characteristics and reproductive function. ARs are activated by binding to androgens, which are steroid hormones such as testosterone and dihydrotestosterone (DHT). Once activated, ARs function as transcription factors that regulate gene expression, ultimately leading to various cellular responses.

In the context of medical definitions, androgen receptors can be defined as follows:

Androgen receptors are a type of nuclear receptor protein that bind to androgens, such as testosterone and dihydrotestosterone, and mediate their effects on gene expression in various tissues. They play critical roles in the development and maintenance of male sexual characteristics and reproductive function, and are involved in the pathogenesis of several medical conditions, including prostate cancer, benign prostatic hyperplasia, and androgen deficiency syndromes.

Muscular dystrophies are a group of genetic disorders that primarily affect skeletal muscles, causing progressive weakness and degeneration. They are characterized by the lack or deficiency of a protein called dystrophin, which is essential for maintaining the integrity of muscle fibers. The most common form is Duchenne muscular dystrophy (DMD), but there are many other types with varying symptoms and severity. Over time, muscle wasting and weakness can lead to disability and shortened lifespan, depending on the type and progression of the disease. Treatment typically focuses on managing symptoms, maintaining mobility, and supporting quality of life.

Spinal cord neoplasms refer to abnormal growths or tumors within the spinal cord. These can be benign (non-cancerous) or malignant (cancerous). They originate from the cells within the spinal cord itself (primary tumors), or they may spread to the spinal cord from other parts of the body (metastatic tumors). Spinal cord neoplasms can cause various symptoms depending on their location and size, including back pain, neurological deficits, and even paralysis. Treatment options include surgery, radiation therapy, and chemotherapy.

A base sequence in the context of molecular biology refers to the specific order of nucleotides in a DNA or RNA molecule. In DNA, these nucleotides are adenine (A), guanine (G), cytosine (C), and thymine (T). In RNA, uracil (U) takes the place of thymine. The base sequence contains genetic information that is transcribed into RNA and ultimately translated into proteins. It is the exact order of these bases that determines the genetic code and thus the function of the DNA or RNA molecule.

A missense mutation is a type of point mutation in which a single nucleotide change results in the substitution of a different amino acid in the protein that is encoded by the affected gene. This occurs when the altered codon (a sequence of three nucleotides that corresponds to a specific amino acid) specifies a different amino acid than the original one. The function and/or stability of the resulting protein may be affected, depending on the type and location of the missense mutation. Missense mutations can have various effects, ranging from benign to severe, depending on the importance of the changed amino acid for the protein's structure or function.

The spinal canal is the bony, protective channel within the vertebral column that contains and houses the spinal cord. It extends from the foramen magnum at the base of the skull to the sacrum, where the spinal cord ends and forms the cauda equina. The spinal canal is formed by a series of vertebral bodies stacked on top of each other, intervertebral discs in between them, and the laminae and spinous processes that form the posterior elements of the vertebrae. The spinal canal provides protection to the spinal cord from external trauma and contains cerebrospinal fluid (CSF) that circulates around the cord, providing nutrients and cushioning. Any narrowing or compression of the spinal canal, known as spinal stenosis, can cause various neurological symptoms due to pressure on the spinal cord or nerve roots.

Hereditary Sensory and Motor Neuropathy (HSMN) is a group of inherited disorders that affect the peripheral nerves, which are the nerves outside the brain and spinal cord. These nerves transmit information between the brain and muscles, as well as sensations such as touch, pain, heat, and cold.

HSMN is characterized by progressive degeneration of these peripheral nerves, leading to muscle weakness, numbness, and tingling sensations, particularly in the hands and feet. The condition can also affect the autonomic nervous system, which controls involuntary functions such as heart rate, blood pressure, and digestion.

HSMN is caused by genetic mutations that are inherited from one or both parents. There are several types of HSMN, each with its own specific symptoms, severity, and pattern of inheritance. The most common form is Charcot-Marie-Tooth disease (CMT), which affects both motor and sensory nerves.

Treatment for HSMN typically focuses on managing the symptoms and preventing complications. This may include physical therapy, bracing or orthopedic surgery to support weakened muscles, pain management, and lifestyle modifications such as avoiding activities that aggravate symptoms. There is currently no cure for HSMN, but ongoing research is aimed at developing new treatments and therapies to slow or halt the progression of the disease.

Genetic therapy, also known as gene therapy, is a medical intervention that involves the use of genetic material, such as DNA or RNA, to treat or prevent diseases. It works by introducing functional genes into cells to replace missing or faulty ones caused by genetic disorders or mutations. The introduced gene is incorporated into the recipient's genome, allowing for the production of a therapeutic protein that can help manage the disease symptoms or even cure the condition.

There are several approaches to genetic therapy, including:

1. Replacing a faulty gene with a healthy one
2. Inactivating or "silencing" a dysfunctional gene causing a disease
3. Introducing a new gene into the body to help fight off a disease, such as cancer

Genetic therapy holds great promise for treating various genetic disorders, including cystic fibrosis, muscular dystrophy, hemophilia, and certain types of cancer. However, it is still an evolving field with many challenges, such as efficient gene delivery, potential immune responses, and ensuring the safety and long-term effectiveness of the therapy.

Heterogeneous Nuclear Ribonucleoproteins (hnRNPs) are a group of nuclear proteins that are involved in the processing and metabolism of messenger RNA (mRNA). They were named "heterogeneous" because they were initially found to be associated with a heterogeneous population of RNA molecules. The hnRNPs are divided into several subfamilies, A and B being two of them.

The hnRNP A-B group is composed of proteins that share structural similarities and have overlapping functions in the regulation of mRNA metabolism. These proteins play a role in various aspects of RNA processing, including splicing, 3' end processing, transport, stability, and translation.

The hnRNP A-B group includes several members, such as hnRNPA1, hnRNPA2/B1, and hnRNPC. These proteins contain RNA recognition motifs (RRMs) that allow them to bind to specific sequences in the RNA molecules. They can also interact with other proteins and form complexes that regulate mRNA function.

Mutations in genes encoding hnRNP A-B group members have been associated with several human diseases, including neurodegenerative disorders, myopathies, and cancer. Therefore, understanding the structure and function of these proteins is essential for elucidating their role in disease pathogenesis and developing potential therapeutic strategies.

Spinal diseases refer to a range of medical conditions that affect the spinal column, which is made up of vertebrae (bones), intervertebral discs, facet joints, nerves, ligaments, and muscles. These diseases can cause pain, discomfort, stiffness, numbness, weakness, or even paralysis, depending on the severity and location of the condition. Here are some examples of spinal diseases:

1. Degenerative disc disease: This is a condition where the intervertebral discs lose their elasticity and height, leading to stiffness, pain, and decreased mobility.
2. Herniated disc: This occurs when the inner material of the intervertebral disc bulges or herniates out through a tear in the outer layer, causing pressure on the spinal nerves and resulting in pain, numbness, tingling, or weakness in the affected area.
3. Spinal stenosis: This is a narrowing of the spinal canal or the neural foramen (the openings where the spinal nerves exit the spinal column), which can cause pressure on the spinal cord or nerves and result in pain, numbness, tingling, or weakness.
4. Scoliosis: This is a curvature of the spine that can occur in children or adults, leading to an abnormal posture, back pain, and decreased lung function.
5. Osteoarthritis: This is a degenerative joint disease that affects the facet joints in the spine, causing pain, stiffness, and decreased mobility.
6. Ankylosing spondylitis: This is a chronic inflammatory disease that affects the spine and sacroiliac joints, leading to pain, stiffness, and fusion of the vertebrae.
7. Spinal tumors: These are abnormal growths that can occur in the spinal column, which can be benign or malignant, causing pain, neurological symptoms, or even paralysis.
8. Infections: Bacterial or viral infections can affect the spine, leading to pain, fever, and other systemic symptoms.
9. Trauma: Fractures, dislocations, or sprains of the spine can occur due to accidents, falls, or sports injuries, causing pain, neurological deficits, or even paralysis.

HeLa cells are a type of immortalized cell line used in scientific research. They are derived from a cancer that developed in the cervical tissue of Henrietta Lacks, an African-American woman, in 1951. After her death, cells taken from her tumor were found to be capable of continuous division and growth in a laboratory setting, making them an invaluable resource for medical research.

HeLa cells have been used in a wide range of scientific studies, including research on cancer, viruses, genetics, and drug development. They were the first human cell line to be successfully cloned and are able to grow rapidly in culture, doubling their population every 20-24 hours. This has made them an essential tool for many areas of biomedical research.

It is important to note that while HeLa cells have been instrumental in numerous scientific breakthroughs, the story of their origin raises ethical questions about informed consent and the use of human tissue in research.

Spinal cord compression is a medical condition that refers to the narrowing of the spinal canal, which puts pressure on the spinal cord and the nerves that branch out from it. This can occur due to various reasons such as degenerative changes in the spine, herniated discs, bone spurs, tumors, or fractures. The compression can lead to a range of symptoms including pain, numbness, tingling, weakness, or loss of bladder and bowel control. In severe cases, it can cause paralysis. Treatment options depend on the underlying cause and may include physical therapy, medication, surgery, or radiation therapy.

A muscle strength dynamometer is a medical device used to measure the force or strength of a muscle or group of muscles. It typically consists of a handheld handle connected to a spring scale or digital force gauge, which measures the amount of force applied by the individual being tested. The person being tested pushes or pulls against the handle with as much force as possible, and the dynamometer provides an objective measurement of their muscle strength in units such as pounds or kilograms.

Muscle strength dynamometers are commonly used in clinical settings to assess muscle weakness or dysfunction, monitor changes in muscle strength over time, and evaluate the effectiveness of rehabilitation interventions. They can be used to test various muscle groups, including the handgrip, quadriceps, hamstrings, biceps, triceps, and shoulder muscles.

When using a muscle strength dynamometer, it is important to follow standardized testing protocols to ensure accurate and reliable measurements. This may include positioning the individual in a specific way, providing standardized instructions, and averaging multiple trials to obtain an accurate measure of their muscle strength.

Medical Definition:

Magnetic Resonance Imaging (MRI) is a non-invasive diagnostic imaging technique that uses a strong magnetic field and radio waves to create detailed cross-sectional or three-dimensional images of the internal structures of the body. The patient lies within a large, cylindrical magnet, and the scanner detects changes in the direction of the magnetic field caused by protons in the body. These changes are then converted into detailed images that help medical professionals to diagnose and monitor various medical conditions, such as tumors, injuries, or diseases affecting the brain, spinal cord, heart, blood vessels, joints, and other internal organs. MRI does not use radiation like computed tomography (CT) scans.

Spinal neoplasms refer to abnormal growths or tumors found within the spinal column, which can be benign (non-cancerous) or malignant (cancerous). These tumors can originate in the spine itself, called primary spinal neoplasms, or they can spread to the spine from other parts of the body, known as secondary or metastatic spinal neoplasms. Spinal neoplasms can cause various symptoms, such as back pain, neurological deficits, and even paralysis, depending on their location and size. Early diagnosis and treatment are crucial to prevent or minimize long-term complications and improve the patient's prognosis.

Polymerase Chain Reaction (PCR) is a laboratory technique used to amplify specific regions of DNA. It enables the production of thousands to millions of copies of a particular DNA sequence in a rapid and efficient manner, making it an essential tool in various fields such as molecular biology, medical diagnostics, forensic science, and research.

The PCR process involves repeated cycles of heating and cooling to separate the DNA strands, allow primers (short sequences of single-stranded DNA) to attach to the target regions, and extend these primers using an enzyme called Taq polymerase, resulting in the exponential amplification of the desired DNA segment.

In a medical context, PCR is often used for detecting and quantifying specific pathogens (viruses, bacteria, fungi, or parasites) in clinical samples, identifying genetic mutations or polymorphisms associated with diseases, monitoring disease progression, and evaluating treatment effectiveness.

Messenger RNA (mRNA) is a type of RNA (ribonucleic acid) that carries genetic information copied from DNA in the form of a series of three-base code "words," each of which specifies a particular amino acid. This information is used by the cell's machinery to construct proteins, a process known as translation. After being transcribed from DNA, mRNA travels out of the nucleus to the ribosomes in the cytoplasm where protein synthesis occurs. Once the protein has been synthesized, the mRNA may be degraded and recycled. Post-transcriptional modifications can also occur to mRNA, such as alternative splicing and addition of a 5' cap and a poly(A) tail, which can affect its stability, localization, and translation efficiency.

A heterozygote is an individual who has inherited two different alleles (versions) of a particular gene, one from each parent. This means that the individual's genotype for that gene contains both a dominant and a recessive allele. The dominant allele will be expressed phenotypically (outwardly visible), while the recessive allele may or may not have any effect on the individual's observable traits, depending on the specific gene and its function. Heterozygotes are often represented as 'Aa', where 'A' is the dominant allele and 'a' is the recessive allele.

Chromosome mapping, also known as physical mapping, is the process of determining the location and order of specific genes or genetic markers on a chromosome. This is typically done by using various laboratory techniques to identify landmarks along the chromosome, such as restriction enzyme cutting sites or patterns of DNA sequence repeats. The resulting map provides important information about the organization and structure of the genome, and can be used for a variety of purposes, including identifying the location of genes associated with genetic diseases, studying evolutionary relationships between organisms, and developing genetic markers for use in breeding or forensic applications.

A "knockout" mouse is a genetically engineered mouse in which one or more genes have been deleted or "knocked out" using molecular biology techniques. This allows researchers to study the function of specific genes and their role in various biological processes, as well as potential associations with human diseases. The mice are generated by introducing targeted DNA modifications into embryonic stem cells, which are then used to create a live animal. Knockout mice have been widely used in biomedical research to investigate gene function, disease mechanisms, and potential therapeutic targets.

Growth cones are specialized structures found at the tips of growing neurites (axons and dendrites) during the development and regeneration of the nervous system. They were first described by Santiago Ramón y Cajal in the late 19th century. Growth cones play a crucial role in the process of neurogenesis, guiding the extension and pathfinding of axons to their appropriate targets through a dynamic interplay with environmental cues. These cues include various guidance molecules, such as netrins, semaphorins, ephrins, and slits, which bind to receptors on the growth cone membrane and trigger intracellular signaling cascades that ultimately determine the direction of axonal outgrowth.

Morphologically, a growth cone consists of three main parts: the central domain (or "C-domain"), the peripheral domain (or "P-domain"), and the transition zone connecting them. The C-domain contains microtubules and neurofilaments, which provide structural support and transport materials to the growing neurite. The P-domain is rich in actin filaments and contains numerous membrane protrusions called filopodia and lamellipodia, which explore the environment for guidance cues and facilitate motility.

The dynamic behavior of growth cones allows them to navigate complex environments, make decisions at choice points, and ultimately form precise neural circuits during development. Understanding the mechanisms that regulate growth cone function is essential for developing strategies to promote neural repair and regeneration in various neurological disorders and injuries.

A muscle is a soft tissue in our body that contracts to produce force and motion. It is composed mainly of specialized cells called muscle fibers, which are bound together by connective tissue. There are three types of muscles: skeletal (voluntary), smooth (involuntary), and cardiac. Skeletal muscles attach to bones and help in movement, while smooth muscles are found within the walls of organs and blood vessels, helping with functions like digestion and circulation. Cardiac muscle is the specific type that makes up the heart, allowing it to pump blood throughout the body.

DNA Mutational Analysis is a laboratory test used to identify genetic variations or changes (mutations) in the DNA sequence of a gene. This type of analysis can be used to diagnose genetic disorders, predict the risk of developing certain diseases, determine the most effective treatment for cancer, or assess the likelihood of passing on an inherited condition to offspring.

The test involves extracting DNA from a patient's sample (such as blood, saliva, or tissue), amplifying specific regions of interest using polymerase chain reaction (PCR), and then sequencing those regions to determine the precise order of nucleotide bases in the DNA molecule. The resulting sequence is then compared to reference sequences to identify any variations or mutations that may be present.

DNA Mutational Analysis can detect a wide range of genetic changes, including single-nucleotide polymorphisms (SNPs), insertions, deletions, duplications, and rearrangements. The test is often used in conjunction with other diagnostic tests and clinical evaluations to provide a comprehensive assessment of a patient's genetic profile.

It is important to note that not all mutations are pathogenic or associated with disease, and the interpretation of DNA Mutational Analysis results requires careful consideration of the patient's medical history, family history, and other relevant factors.

Antisense oligonucleotides (ASOs) are short synthetic single stranded DNA-like molecules that are designed to complementarily bind to a specific RNA sequence through base-pairing, with the goal of preventing the translation of the target RNA into protein or promoting its degradation.

The antisense oligonucleotides work by hybridizing to the targeted messenger RNA (mRNA) molecule and inducing RNase H-mediated degradation, sterically blocking ribosomal translation, or modulating alternative splicing of the pre-mRNA.

ASOs have shown promise as therapeutic agents for various genetic diseases, viral infections, and cancers by specifically targeting disease-causing genes. However, their clinical application is still facing challenges such as off-target effects, stability, delivery, and potential immunogenicity.

Progressive bulbar palsy (PBP) is a form of motor neuron disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS). It is characterized by the progressive degeneration of the motor neurons in the brainstem, which control vital functions such as swallowing, speaking, chewing, and breathing.

In PBP, these symptoms gradually worsen over time, often resulting in severe disability and ultimately death due to respiratory failure. The progression of the disease can vary from person to person, but it typically advances more slowly than other forms of ALS. There is currently no cure for PBP or any other form of MND, and treatment is focused on managing symptoms and maintaining quality of life.

DSMA1 is usually fatal in early childhood. The patient, normally a child, suffers a progressive degradation of the respiratory ... Distal spinal muscular atrophy type 1 (DSMA1), also known as spinal muscular atrophy with respiratory distress type 1 (SMARD1 ... Distal hereditary motor neuropathies Spinal muscular atrophies Spinal muscular atrophy Messina, M. F.; Messina, S.; Gaeta, M.; ... There is no published practice standard for the care in DSMA1, even though the Spinal Muscular Atrophy Standard of Care ...
The disorder is frequently fatal in early childhood. The disease is caused by a mutation in the BICD2 gene and is passed on in ... Spinal muscular atrophies Spinal muscular atrophy with lower extremity predominance 1 Spinal muscular atrophy with lower ... Spinal muscular atrophy with lower extremity predominance 2B (SMALED2B) is a rare neuromuscular disorder characterised by ... "In-frame de novo mutation in BICD2 in two patients with muscular atrophy and arthrogryposis". Cold Spring Harbor Molecular Case ...
"Abnormal fatty acid metabolism in childhood spinal muscular atrophy". Annals of Neurology. 45 (3): 337-43. doi:10.1002/1531- ... "Spinal Muscular Atrophy". NORD (National Organization for Rare Disorders). Retrieved 27 May 2019. "Spinal muscular atrophy". ... "Spinal muscular atrophy: MedlinePlus Genetics". medlineplus.gov. Retrieved 24 October 2020. "Spinal Muscular Atrophy (SMA) , ... "Spinal muscular atrophy". Genetics Home Reference. Retrieved 27 May 2019. "Spinal Muscular Atrophy - Conditions , Children's ...
"Abnormal fatty acid metabolism in childhood spinal muscular atrophy". Annals of Neurology. 45 (3): 337-343. doi:10.1002/1531- ... "Fatty acid oxidation abnormalities in childhood-onset spinal muscular atrophy: Primary or secondary defect(s)?". Pediatric ... disease Fabry disease Farber's disease Gangliosidoses Krabbé disease Metachromatic leukodystrophy Spinal muscular atrophy ...
"Spinal muscular atrophy of childhood at the edge of the centuries". Functional Neurology. 16 (4 Suppl): 247-53. PMID 11996521. ... Liu Q, Fischer U, Wang F, Dreyfuss G (September 1997). "The spinal muscular atrophy disease gene product, SMN, and its ... Mutations in SMN1 are associated with spinal muscular atrophy. Mutations in SMN2 alone do not lead to disease, although ... "Spinal muscular atrophy due to an isolated deletion of exon 8 of the telomeric survival motor neuron gene". Annals of Neurology ...
"Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3". primary. Nature. 344 (6266): 540 ... Spinal muscular atrophy is linked to genetic mutations in the SMN1 (Survival of Motor Neuron 1) gene. The SMN protein is widely ... Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease caused by mutations in the SMN1 gene. Symptoms ... This article will cover the epigenetics and treatment of amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA ...
The disorder is usually fatal in infancy or early childhood due to progressive respiratory failure, although survival into ... in the spinal cord and brain stem A child with these symptoms are likely to have X-linked spinal muscular atrophy. In order to ... Spinal muscular atrophies Arthrogryposis Ramser, J.; Ahearn, M. E.; Lenski, C.; Yariz, K. O.; Hellebrand, H.; Von Rhein, M.; ... X-linked spinal muscular atrophy type 2 (SMAX2, XLSMA), also known as arthrogryposis multiplex congenita X-linked type 1 (AMCX1 ...
Among the various disorders associated with the ubiquitin-proteasome pathway is X-linked infantile spinal muscular atrophy (XL- ... SMA). The fatal childhood disorder is associated with loss of anterior horn cells and infantile death. Clinical features ... January 2008). "Rare Missense and Synonymous Variants in UBE1 Are Associated with X-Linked Infantile Spinal Muscular Atrophy". ...
People with spinal muscular atrophy, People with speech impediment, Blind musicians, German blind people, Blind royalty and ... He was disabled due to a paralytic disease from early childhood. He was born on 18 July 1013 with a cleft palate and cerebral ... more recent scholarship indicates Hermann possibly had either amyotrophic lateral sclerosis or spinal muscular atrophy. As a ...
... is a very rare childhood-onset genetic disorder characterised by progressive muscle wasting affecting lower and subsequently ... Spinal muscular atrophies Distal hereditary motor neuropathies Christodoulou, K; Zamba, E; Tsingis, M; Mubaidin, A; Horani, K; ... Distal spinal muscular atrophy type 2 (DSMA2), also known as Jerash type distal hereditary motor neuropathy (HMNJ), ... v t e v t e (Articles with short description, Short description is different from Wikidata, Muscular disorders, Genetic ...
Samoylova began losing function of her legs due to spinal muscular atrophy and has used a wheelchair since childhood. The ... People with spinal muscular atrophy, Russian pop singers, Russian people with disabilities, The X Factor contestants, 21st- ...
... the national publication of the Spinal Muscular Atrophy Association) (Directions Magazine of the Spinal Muscular Atrophy ... Because she was wheelchair-reliant since childhood, Sheypuk has used her personal story in her advocacy work, aiming to break ... She was born with spinal muscular atrophy and got her first motorized wheelchair in kindergarten. After graduating from ... People with spinal muscular atrophy, 21st-century American women, American scientists with disabilities). ...
... a type of spinal muscular atrophy). It was first documented in 1897 by Johann Hoffmann. It has adult-onset symptoms and is ... childhood-onset hypothyroid myopathy), Glycogen storage disease (GSD-V, & late-onset GSD-II), Non-dystrophic myotonias and ... Muscle biopsy of hypothyroid myopathy shows atrophy of type II (fast-twitch/glycolytic) muscle fibres and a predominance of ... pseudomyotonias (such as Myotonia congenita and Brody disease), Limb-girdle muscular dystrophy, Duchenne and Becker muscular ...
... born with spinal muscular atrophy) Sir Winston Churchill, MP between 1901 and 1964, twice Prime Minister of the United Kingdom ... blind due to childhood cancer) Daniel Inouye, former U.S. Senator from Hawaii (lost his right arm due to grenade shrapnel in ... wheelchair user due to spinal muscular atrophy) Charles II of Spain, ruled 1665-1700, described by historians Will and Ariel ... wheelchair user due to spinal muscular atrophy) Enrico Dandolo (1107?-1205), 42nd Doge of Venice (blind) Claudius, 4th Roman ...
... muscular atrophy, spinal MeSH C10.228.854.468.800 - spinal muscular atrophies of childhood MeSH C10.228.854.525 - myelitis MeSH ... muscular atrophy, spinal MeSH C10.668.460.500.750 - spinal muscular atrophies of childhood MeSH C10.668.460.600 - poliomyelitis ... muscular atrophy, spinal MeSH C10.574.562.500.750 - spinal muscular atrophies of childhood MeSH C10.574.625.600 - ... spinal muscular atrophies of childhood MeSH C10.668.491.175 - muscular disorders, atrophic MeSH C10.668.491.175.500 - muscular ...
Spinal muscular atrophy with congenital degeneration of anterior horns of spinal cord. Autosomal recessive Wiedemann-Steiner ... childhood mercury poisoning) Autoimmunity disorders Myasthenia gravis - most common Abnormal vaccine reaction Celiac disease ... Spinal muscular atrophy (SMA) Succinic semialdehyde dehydrogenase deficiency (SSADH) Tay-Sachs disease Werdnig-Hoffmann ... most common Metachromatic leukodystrophy Rett syndrome Spinal muscular atrophy Infections Encephalitis Guillain-Barré syndrome ...
... spinal muscular atrophies of childhood MeSH C16.320.400.780 - spinocerebellar degenerations MeSH C16.320.400.780.200 - ... gyrate atrophy MeSH C16.320.290.564 - optic atrophies, hereditary MeSH C16.320.290.564.400 - optic atrophy, hereditary, leber ... muscular dystrophies, limb-girdle MeSH C16.320.577.300 - muscular dystrophy, Duchenne MeSH C16.320.577.350 - muscular dystrophy ... optic atrophies, hereditary MeSH C16.320.400.630.400 - optic atrophy, hereditary, leber MeSH C16.320.400.630.500 - optic ...
... predicted that the infantile and childhood forms of spinal muscular atrophy and of adult-onset proximal muscle atrophy were ... she published papers on muscular dystrophy and multiple myeloma. Spinal muscular atrophy, first described by Johann Hoffmann ... Byers, Randolph K.; Banker, Betty Q. (1961). "Infantile Muscular Atrophy". Archives of Neurology. 5 (2): 140-164. doi:10.1001/ ... She was active in the Muscular Dystrophy Association of America and held many roles, including Vice President and member of the ...
Founded by Srin Madipalli and Martyn Sibley, two childhood friends who have Spinal Muscular Atrophy, the company was based in ...
Since Zolgensma is the only approved drug for curing Spinal Muscular Atrophy in childhood, patients who cannot afford Zolgensma ...
Customers spotlighted include comics blogger/journalist Jill Pantozzi, who was diagnosed at age 2 with spinal muscular atrophy ... include Gladston assigning Rae the task of tracking down a difficult-to-find copy of the comic book that began his childhood ... who was diagnosed at age 2 with spinal muscular atrophy, but interacts with other comics fans on her blog and at conventions. ...
S, Corinne; More, s on I. love losing my... Read (2019-11-25). "Woman With Spinal Muscular Atrophy Shares Moment She Finds Out ... Dectis says her childhood in the entertainment industry made her realize the importance of protecting children in the industry ... Diagnosed with type 2 spinal muscular atrophy as a child, she uses a wheelchair. Dectis was born March 5, 1993, in Allentown, ... She was diagnosed with spinal muscular atrophy at 16 months and has used an electric wheelchair since age two. Dectis graduated ...
... protected skeletal muscles from cell death and atrophy and extended survival by 40% in an animal model of spinal muscular ... Kansagra S, Mikati MA, Vigevano F (2013). "Alternating hemiplegia of childhood". Pediatric Neurology Part II. Handbook of ... flunarizine increases SMN protein in nuclear Cajal bodies and motor function in a mouse model of spinal muscular atrophy". ... Flunarizine extended motor neuron survival in spinal cord, ... atrophy. Flunarizine has also shown promise as an anti-prion ...
The ASAH1 gene is also known to cause a condition called spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME ... Individuals with moderate or attenuated forms may develop symptoms at any time in childhood. Sometimes it is difficult to ... Lee, BH; Mongiovi, P; Levade, T; Marston, B; Mountain, J; Ciafaloni, E (October 2020). "Spinal muscular atrophy and Farber ... Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy". Human Mutation. 41 (9): 1469-1487. doi:10.1002 ...
Waxman Fiduccia was born with spinal muscular atrophy and used an external ventilation system until she had a tracheostomy in ... Fiduccia also used a wheelchair as a result of childhood cancer. They fought the Social security Administration for their right ... People with spinal muscular atrophy, Educators with disabilities). ...
Tooth disease Hereditary motor neuropathies Hereditary sensory and autonomic neuropathies Spinal muscular atrophies Charcot- ... Onset of HMSN is most common in early childhood, with clinical effects occurring before the age of 10, but some symptoms are ... These symptoms are a result of severe muscular weakness and atrophy. In patients with demyelinating neuropathy, symptoms are ... Dyck, Peter James; Lambert, Edward H. (1968). "Lower Motor and Primary Sensory Neuron Diseases With Peroneal Muscular Atrophy ...
... alterations found in patient with Fazio-Londe disease were identical to those seen in infantile-onset spinal muscular atrophy.[ ... Fazio-Londe disease (FLD), also called progressive bulbar palsy of childhood, is a very rare inherited motor neuron disease of ... The most frequent symptoms at onset of progressive bulbar paralysis of childhood has been a unilateral facial paralysis. It is ... Other cranial nerves involved were vagus, trigeminal, spinal accessory nerve, abducens, oculomotor and glossopharyngeal in this ...
Chronic heart failure Spinal muscular atrophy: symptoms include exercise intolerance, cognitive impairment and fatigue. ... Hypothyroid myopathy includes Kocher-Debre-Semelaigne syndrome (childhood-onset) and Hoffmann syndrome (adult-onset). Metabolic ... Multiple sclerosis Cystic fibrosis: CF can cause skeletal muscle atrophy, however more commonly it can cause exercise ...
... ataxia-retinitis pigmentosa syndrome Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy ... Autosomal recessive ataxia due to ubiquinone deficiency Adult-onset autosomal recessive cerebellar ataxia Childhood-onset ...
... muscular dystrophy, cleft lip and palate, limb-length discrepancy, spinal muscular atrophy and osteogenesis imperfecta. ... Gillette doesn't treat common childhood illnesses or cancer. Children who have disabilities often need a more advanced level of ... brain and spinal cord injury, epilepsy and seizures, torticollis, hydrocephalus, craniosynostosis, spina bifida, ...
Spinal muscular atrophy (SMA) is a progressive, autosomal recessive neuromuscular disorder caused by a mutation of the SMN1 ... Effect on maximal mouth opening in children with spinal muscular atrophy treated with onasemnogene abeparvovec ... Effect on maximal mouth opening in children with spinal muscular atrophy treated with onasemnogene abeparvovec ... This causes progressive muscle weakness and muscle atrophy. The voluntary muscles are affected, including those involved in ...
Effect on maximal mouth opening in children with spinal muscular atrophy treated with onasemnogene abeparvovec ... Effect on maximal mouth opening in children with spinal muscular atrophy treated with onasemnogene abeparvovec ... Effect on maximal mouth opening in children with spinal muscular atrophy treated with onasemnogene abeparvovec ...
... atrophy) in the lower limbs, most severely affecting the thigh muscles (quadriceps). Explore symptoms, inheritance, genetics of ... Spinal muscular atrophy with lower extremity predominance (SMA-LED) is characterized by muscle weakness and wasting ( ... Spinal muscular atrophy, childhood, proximal, autosomal dominant. *Spinal muscular atrophy, juvenile, proximal, autosomal ... SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 1, AUTOSOMAL DOMINANT; SMALED1. *SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY ...
In the early 1980s, Werdnig and Hoffman described a disorder of progressive muscular weakness beginning in infancy that ... The spinal muscular atrophies (SMAs) comprise a group of autosomal-recessive disorders characterized by progressive weakness of ... Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012 May. 11(5):443-52. [QxMD MEDLINE Link]. ... encoded search term (Spinal Muscular Atrophy) and Spinal Muscular Atrophy What to Read Next on Medscape ...
DSMA1 is usually fatal in early childhood. The patient, normally a child, suffers a progressive degradation of the respiratory ... Distal spinal muscular atrophy type 1 (DSMA1), also known as spinal muscular atrophy with respiratory distress type 1 (SMARD1 ... Distal hereditary motor neuropathies Spinal muscular atrophies Spinal muscular atrophy Messina, M. F.; Messina, S.; Gaeta, M.; ... There is no published practice standard for the care in DSMA1, even though the Spinal Muscular Atrophy Standard of Care ...
Childhood spinal muscular atrophy. Younger, David S; Mendell, Jerry R. Afiliação *Younger DS; Department of Clinical Medicine ... Spinal muscular atrophy (SMA) is caused by biallelic mutations in the SMN1 (survival motor neuron 1) gene on chromosome 5q13.2 ... Anterior horn cell; Disease-modifying therapy; Motor neuron disease; SMN1 gene; Spinal muscular atrophy ... Atrofia Muscular Espinal; Criança; Humanos; Atrofia Muscular Espinal/genética; Neurônios Motores; Genes Reguladores; Tronco ...
Living with spinal muscular atrophy (SMA) is challenging. Staying informed about SMA is key to ensuring that your child has a ... Obesity may be a concern for children with SMA who live beyond early childhood, as theyre less able to be active than children ... Types:Spinal muscular atrophy. (2017).. http://www.nhs.uk/Conditions/Spinal-muscular-atrophy/Pages/symptoms.aspx. ... Spinalmuscular atrophy: Signs and symptoms. (n.d.).. https://www.mda.org/disease/spinal-muscular-atrophy/signs-and-symptoms. ...
... represent a rare group of inherited disorders that cause progressive degeneration of the anterior horn cells of the spinal cord ... Moosa A, Dubowitz V. Spinal muscular atrophy in childhood. Two clues to clinical diagnosis. Arch Dis Child. 1973 May. 48(5):386 ... encoded search term (Kugelberg Welander Spinal Muscular Atrophy) and Kugelberg Welander Spinal Muscular Atrophy What to Read ... A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III ...
... protein that affects alpha motoneurons in the spinal cord. Notch signaling is a cell-cell communication system well known as a ... Spinal muscular atrophy (SMA) is a neurodegenerative disease produced by low levels of Survival Motor Neuron (SMN) ... model of SMA we also found increased astrocyte processes positive for Jagged1 and Delta1 in intimate contact with lumbar spinal ... Crawford, T.O.; Pardo, C.A. The neurobiology of childhood spinal muscular atrophy. Neurobiol. Dis 1996, 3, 97-110. [Google ...
Spinal muscular Atrophy (SMA) is a childhood form of Motor Neurone Disease. It is caused by a defect in a gene which 1:35 of us ... Vascular Defects and Spinal Cord Hypoxia in Spinal Muscular Atrophy. 2016 - Published. ... Microvascular abnormality in spinal muscular atrophy and its response to antisense oligonucleotide therapy. 2015 - Published. ... Altered retinal vasculature is a biomarker of disease in Spinal Muscular Atrophy in mouse models and human patients. 2021 - ...
Spinal muscular Atrophy (SMA) is a childhood form of Motor Neurone Disease. It is caused by a defect in a gene which 1:35 of us ...
Learn about progressive muscular atrophy (PMA), a rare adult-onset disease that affects your lower motor neurons. ... Can Adults Get Spinal Muscular Atrophy?. Though rare, adults can get spinal muscular atrophy. When SMA symptoms begin in ... adulthood, the outlook is often better than if it begins in childhood. ... Distal Spinal Muscular Atrophy: What You Need To Know. Distal spinal muscular atrophy primarily impacts the hands and feet ...
... care and advocacy for people living with muscular dystrophy, ALS, and related neuromuscular diseases. ... Spinal Muscular Atrophies. In: Vivo BTD, ed. Neuromuscular Disorders of Infancy, Childhood, and Adolescence (Second Edition). ... Spinal Muscular Atrophy (SMA) is characterized by loss of motor neurons in the spinal cord and lower brain stem, resulting in ... Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002;4(1):20-26. ...
A senior doctor is urging couples planning on starting a family to undergo genetic testing for Spinal Muscular Atrophy - a ... SMA Type One is childhood version of Motor Neurone Disease, and the biggest genetic killer of children under the age of two in ... According to Spinal Muscular Atrophy Australia Inc. all SMA children appear normal at birth before the deterioration and loss ... A just 13 months old, Aviana suffers from Spinal Muscular Atrophy Type One, a rare genetic condition that causes progressive ...
Abnormal fatty acid metabolism in childhood spinal muscular atrophy. Ann Neurol 1999;45:337-343. Table 1 -- SMA Type 1 Group ... Spinal muscular atrophy. Semin Neurol 1998;18:19-26. 2. Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an ... Spinal muscular atrophy; Mechanical ventilation; Respiratory insufficiency; Outcomes. Introduction. The spinal muscular ... Spinal Muscular Atrophy Type 1: Management and Outcomes by John R. Bach, MD. Reference: Bach JR, Baird JS, Plosky D, Nevado J, ...
Routine sampling and analysis of newborn DNA would enable screening for hundreds of childhood genetic diseases, but also raises ... a neonatal genetic screening project focusing on childhood spinal muscular atrophy, fragile X syndrome, and Duchenne muscular ... To date, in France, the only genetic screening authorized is for childhood spinal muscular atrophy via identification of an ... "If we are able to identify the 40 newborns affected by spinal muscular atrophy from birth, we can offer these patients gene ...
... for spinal muscular atrophy (SMA).. Spinal muscular atrophy is a condition that affects the nervous system and caused ... a lethal childhood muscle-wasting disorder. Results from the study, published in the journal Nature Biotechnology, were so ... They have used a drug to help increase the levels of a crucial nerve protein missing in patients with spinal muscular atrophy ( ... Genetic testing for cystic fibrosis, fragile X syndrome and spinal muscular atrophy is recommended for all would-be parents by ...
The Annabelle Rose Foundation for Spinal Muscular Atrophy. Let the training (re)commence! The next cycle challenge for The ... Reelin for Research is a year-round fundraising effort benefiting the UNC Childrens Hospital in support of childhood cancer ... To date, over 6 million dollars has been raised to help LAND A CURE for childhood cancer! ...
Spinal muscular atrophy (SMA), the most common form of neurodegenerative disease in childhood, is caused by defects in the SMN1 ... Experts encourage earlier intervention for some infants with spinal muscular atrophy. ...
Patients exposed to childhood maltreatment were at greater risk for developing atopic disease compared with unexposed ... A cross-sectional study suggests that spinal muscular atrophy (SMA) can contribute to cognitive impairment. ... A cross-sectional study suggests that spinal muscular atrophy (SMA) can contribute to cognitive impairment. ... Exposure to childhood maltreatment in the exposed group was indicated to occur at a mean (SD) age of 6.05 (5.24) years. Average ...
Mutations in the gene coding for survival of motor neuron 1 protein may result in SPINAL MUSCULAR ATROPHIES OF CHILDHOOD. ... Activation of Muscle-Specific Kinase (MuSK) Reduces Neuromuscular Defects in the Delta7 Mouse Model of Spinal Muscular Atrophy ... Genetic modifiers ameliorate endocytic and neuromuscular defects in a model of spinal muscular atrophy. BMC Biol. 2020 09 16; ... Whole blood survival motor neuron protein levels correlate with severity of denervation in spinal muscular atrophy. Muscle ...
His mothers cousin gave birth late last year to a boy with a rare, often fatal genetic disease called spinal muscular atrophy ... He followed his engineer father to Santiago, an hour and then some away from his childhood home. Santiago, he knew, would be ...
... change the way that specialists and researchers think about a childhood muscle-wasting disease called spinal muscular atrophy. ... Top trainee hopes his unexpected discovery may help children with spinal muscular atrophy October 26, 2017 ... called Spinal Muscular Atrophy, or SMA. Now, five years later, Deguise has helped make a major discovery that has shaken up ...
For Christoph Keller, it was different: his childhood diagnosis with a form of Spinal Muscular Atrophy only revealed what had ... For Christoph Keller, it was different: his childhood diagnosis with a form of Spinal Muscular Atrophy only revealed what had ...
website Childhood Dementia Initiative facebook Childhood Dementia Initiative instagram Childhood Dementia Initiative twitter ... Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome. Get in touch with RARE Concierge ... Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome?. Our RARE Concierge Services ... Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome. A rare genetic neurodegenerative ...
Spinal Muscular Atrophies (SMAs) - Etiology, pathophysiology, symptoms, signs, diagnosis & prognosis from the MSD Manuals - ... Manifestations may begin in infancy or childhood. They vary by the specific type and may include hypotonia; hyporeflexia; ... Spinal muscular atrophy type 1 (infantile spinal muscular atrophy, or Werdnig-Hoffmann disease) is also present in utero and ... Spinal muscular atrophy type 3 (juvenile form, or Wohlfart-Kugelberg-Welander disease) usually manifests between age 15 months ...
Spinal Muscular Atrophy and dominant forms of Spinocerebellar Ataxia. Interested researchers should refer to the relevant JPND ... However, childhood dementias/neurodegenerative diseases are not excluded.. *Rare infectious diseases, rare cancers and rare ...
Born with spinal muscular atrophy, Sena has been using a wheelchair since childhood. She wants to change the negative views ... He has a physical disability due to a spinal cord injury at 15. His body movement is limited to above the neck. He uses a stick ... Daisuke was born with Charcot-Marie-Tooth syndrome, a progressive muscle atrophy disability. He has been using a wheelchair for ... Duchenne muscular dystrophy), Ryoga has been an active and outspoken disability advocate and activist. For example, he wrote ...
... represent a rare group of inherited disorders that cause progressive degeneration of the anterior horn cells of the spinal cord ... Moosa A, Dubowitz V. Spinal muscular atrophy in childhood. Two clues to clinical diagnosis. Arch Dis Child. 1973 May. 48(5):386 ... encoded search term (Kugelberg Welander Spinal Muscular Atrophy) and Kugelberg Welander Spinal Muscular Atrophy What to Read ... A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III ...
... represent a rare group of inherited disorders that cause progressive degeneration of the anterior horn cells of the spinal cord ... Moosa A, Dubowitz V. Spinal muscular atrophy in childhood. Two clues to clinical diagnosis. Arch Dis Child. 1973 May. 48(5):386 ... encoded search term (Kugelberg Welander Spinal Muscular Atrophy) and Kugelberg Welander Spinal Muscular Atrophy What to Read ... A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III ...
  • The spinal muscular atrophies (SMAs) comprise a group of autosomal-recessive disorders characterized by progressive weakness of the lower motor neurons. (medscape.com)
  • Spinal muscular atrophies (SMAs) represent a rare group of inherited disorders that cause progressive degeneration of the anterior horn cells of the spinal cord. (medscape.com)
  • SMAs were first described in the 1890s, by Guido Werdnig, a physician from the University of Vienna, in his lecture "On a Case of Muscular Dystrophy with Positive Spinal Cord Findings. (medscape.com)
  • The spinal muscular atrophies (SMAs) are inherited as autosomal recessive disorders of anterior horn cells with the genetic defect at chromosome 5q13. (doctorbach.com)
  • It treats a group of rare genetic disorders called spinal muscular atrophies (SMAs) that cause loss of nerve cells that control skeletal muscles (muscles that allow us to move) leading to weakness. (medlineplus.gov)
  • SMAs start in infancy or early childhood and are a leading cause of death in infants and toddlers. (medlineplus.gov)
  • Recent advances in the treatment of spinal muscular atrophy (SMA) have dramatically altered prognosis. (dovepress.com)
  • Because early testing and treatment of spinal muscular atrophy (SMA) may improve quality of life and slow disease progression, follow-up testing must be conducted as soon as possible to determine whether or not your baby has the condition. (babysfirsttest.org)
  • More than 95% of patients with spinal muscular atrophy have a homozygous disruption in the SMN1 gene on chromosome 5q, caused by mutation, deletion, or rearrangement. (medscape.com)
  • However, all patients with spinal muscular atrophy retain at least 1 copy of SMN2 , which generates only 10% of the amount of full-length SMN protein versus SMN1 . (medscape.com)
  • Patients with spinal muscular atrophy (SMA) should have frequent follow-up care for symptomatic control of their disease. (medscape.com)
  • Patients with spinal muscular atrophy experience a progressive loss of motor function that usually affects the legs before it does the arms, and the proximal muscles before the distal ones. (medscape.com)
  • Pulmonary function assessment in patients with spinal muscular atrophy type II and type III. (medscape.com)
  • The central role of lower motor neuron degeneration was confirmed in subsequent pathologic studies demonstrating a loss of anterior horn cells in the spinal cord and cranial nerve nuclei. (medscape.com)
  • Distal spinal muscular atrophy type 1 (DSMA1), also known as spinal muscular atrophy with respiratory distress type 1 (SMARD1), is a rare neuromuscular disorder involving death of motor neurons in the spinal cord which leads to a generalised progressive atrophy of body muscles. (wikipedia.org)
  • Spinal muscular atrophy (SMA) is caused by biallelic mutations in the SMN1 ( survival motor neuron 1) gene on chromosome 5q13.2, which leads to a progressive degeneration of alpha motor neurons in the spinal cord and in motor nerve nuclei in the caudal brainstem . (bvsalud.org)
  • The medication is injected into the fluid surrounding the spinal cord. (healthline.com)
  • Both physicians conducted autopsies on their patients and found severe atrophy of the ventral roots of the spinal cord. (medscape.com)
  • Spinal muscular atrophy (SMA) is a neurodegenerative disease produced by low levels of Survival Motor Neuron (SMN) protein that affects alpha motoneurons in the spinal cord. (mdpi.com)
  • Lower motor neurons transmit signals between your spinal cord and muscles. (healthline.com)
  • The signs and symptoms of PMA can resemble those of several other conditions, including multiple sclerosis , amyotrophic lateral sclerosis (ALS), and brain and spinal cord tumors. (healthline.com)
  • Spinal muscular atrophies include several types of hereditary disorders characterized by skeletal muscle wasting due to progressive degeneration of anterior horn cells in the spinal cord and of motor nuclei in the brain stem. (msdmanuals.com)
  • Muscle atrophy, caused by a progressive loss of the anterior horn cells in the spinal cord, is universal. (medscape.com)
  • Spinal muscular atrophy (SMA) is an autosomal recessive, inherited genetic disease characterized by degeneration of alpha motor neurons in the spinal cord. (dovepress.com)
  • Performing post-mortem staging of the brains and spinal cord tissue of patients with ALS, researchers discover the neurodegenerative disease could progress from one start point in the CNS to other regions of the brain and spinal cord. (neurosciencenews.com)
  • SMA is a gene mutation, or mixed-up gene information, on the gene that produces proteins necessary for the nerve cells in the spinal cord that control your muscles. (hospitalroad.com)
  • Spinal cord nerves deprived of the protein affected will die prematurely, leaving the muscles they control drastically weakened. (hospitalroad.com)
  • ALS, or "Lou Gehrig¹s Disease," is a fatal neurological disorder that attacks motor cells in the spinal cord and brain. (sciencedaily.com)
  • Spinal muscular atrophy, also characterized by degeneration of motor cells in the spinal cord and brain, is the second most common neuromuscular disorder of childhood, after Duchenne Muscular Dystrophy. (sciencedaily.com)
  • Spinal muscular atrophy (SMA) is a group of inherited conditions that affect the motor neurons of the spinal cord. (babysfirsttest.org)
  • Spinal muscular atrophy (SMA) affects the motor nerves in the spinal cord essentially robbing the sufferers of their strength. (belmarrahealth.com)
  • The results of the study showed that 77 percent of spinal cord injury patients have symptomatic sleep-disordered breathing and 92 percent have poor sleep quality. (belmarrahealth.com)
  • Dr. Abdulghani Sankari, lead author, said, "The majority of spinal cord injury survivors have symptomatic sleep-disordered breathing and poor sleep that may be missed if not carefully assessed. (belmarrahealth.com)
  • Our findings help in identifying the mechanism of sleep-disordered breathing in spinal cord injury and may provide potential targets for new treatment. (belmarrahealth.com)
  • Sleep-disordered breathing may contribute to increased cardiovascular mortality in spinal cord injury patients. (belmarrahealth.com)
  • All spinal cord injury patients should undergo a comprehensive sleep evaluation using full, overnight polysomnography for the accurate diagnosis of sleep apnea," added Dr. M. Safwan Badr who was also involved in the study. (belmarrahealth.com)
  • The researchers studied 26 chronic spinal cord injury patients who all underwent baseline spirometry, filled out a number of questionnaires, and attended polysomnography with flow and pharyngeal pressure measurements. (belmarrahealth.com)
  • SB affects the development of the spine and spinal cord before birth, and can result in leg weakness and paralysis. (biomedcentral.com)
  • The spinal muscular atrophies are the second most common autosomal-recessive inherited disorders after cystic fibrosis . (medscape.com)
  • Spinal muscular atrophies may involve the central nervous system and thus are not purely peripheral nervous system disorders. (msdmanuals.com)
  • These kinds of genetic medicines also have the potential for treating genetic defects that cause other neurological disorders including other rare muscular disorders. (medlineplus.gov)
  • In North Carolina, 25,000 newborns took part in the Early Check study, a neonatal genetic screening project focusing on childhood spinal muscular atrophy , fragile X syndrome , and Duchenne muscular dystrophy . (medscape.com)
  • This article describes two rare diseases - spinal muscular atrophy and Duchenne muscular dystrophy - and how NIH supports research and development on gene therapies to treat them. (medlineplus.gov)
  • Duchenne muscular dystrophy (or DMD) is the most common muscular dystrophy in children, and it mostly affects boys in early childhood. (medlineplus.gov)
  • Serum creatine kinase levels may be elevated but usually not to the extent that they are elevated in persons with muscular dystrophy. (medscape.com)
  • Muscular Dystrophy Campaign sponsored workshop: recommendation for respiratory care of children with SMA type II and III. (medscape.com)
  • New SPINRAZA data continue to reinforce the positive results seen in clinical studies and in my own practice," said Thomas Crawford, M.D., co-director, Muscular Dystrophy Association Clinic at Johns Hopkins Medicine. (biogen.com)
  • August is Spinal Muscular Atrophy Awareness Month , so we are presenting to you a selection of our articles on spinal muscular atrophy and related topics, like muscular dystrophy, obstructive sleep apnea, scoliosis, and back pain. (belmarrahealth.com)
  • Muscular dystrophy is a group of diseases that cause progressive muscle weakness and loss of muscle mass. (belmarrahealth.com)
  • There are different types of muscular dystrophy. (belmarrahealth.com)
  • Over time, muscular dystrophy can impair a person's ability to walk. (belmarrahealth.com)
  • There is currently no cure for muscular dystrophy, but treatments can help manage the condition and slow down its progression. (belmarrahealth.com)
  • Other relevant conditions included muscular dystrophy, spinal muscular atrophy and congenital clubfoot. (biomedcentral.com)
  • Spinal muscular atrophy with lower extremity predominance (SMA-LED) is characterized by muscle weakness and wasting (atrophy) in the lower limbs, most severely affecting the thigh muscles (quadriceps). (medlineplus.gov)
  • Spinal muscular atrophy , lower extremity, dominant (SMA-LED) is characterized by leg muscle weakness that is most severe in the thigh muscles (quadriceps). (unitedspinal.org)
  • The mortality and/or morbidity rates of spinal muscular atrophy are inversely correlated with the age at onset. (medscape.com)
  • Male individuals are most frequently affected, especially with the early-onset forms of spinal muscular atrophy, ie, types I and II. (medscape.com)
  • Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. (medscape.com)
  • Progressive muscular atrophy (PMA) is a rare adult-onset motor neuron disease. (healthline.com)
  • CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE) --Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) announced that SPINRAZATM (nusinersen), an investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint at the interim analysis of CHERISH, the Phase 3 study evaluating SPINRAZA in later-onset (consistent with Type 2) SMA. (mda.org)
  • Newly diagnosed with Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome? (globalgenes.org)
  • Spinal muscular atrophy type 4 (late-onset) can be recessive, dominant, or X-linked, with adult onset (age 30 to 60 years) and slow progression of primarily proximal muscle weakness and wasting. (msdmanuals.com)
  • A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. (medscape.com)
  • The study findings have implications for genomic testing or screening for highly penetrant childhood-onset rare diseases that cause serious physical and mental problems or early death, e.g., spinal muscular atrophy (SMA). (cdc.gov)
  • SMA has three major childhood forms classified by age of onset. (sciencedaily.com)
  • Ewout now works in the laboratory of Prof Gillingwater in Edinburgh studying the childhood-onset MND spinal muscular atrophy. (bitesizebio.com)
  • The breadth of data presented reinforces the significant and clinically meaningful efficacy of SPINRAZA on the achievement of motor milestones and measures of motor function across a broad range of individuals with spinal muscular atrophy (SMA), as well as on survival endpoints in infantile-onset SMA. (biogen.com)
  • Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): End of study results from the phase 3 CHERISH. (biogen.com)
  • An adult-onset form of spinal muscular atrophy that begins in early to mid-adulthood affects the proximal muscles and is characterized by muscle cramping of the limbs and abdomen, weakness in the leg muscles, involuntary muscle contractions, tremors, and a protrusion of the abdomen thought to be related to muscle weakness. (unitedspinal.org)
  • The age of onset and signs of spinal muscular atrophy (SMA) differ depending on the form. (babysfirsttest.org)
  • Unlike 50 years ago, when intermediate SMA was considered a life-limiting condition, developments in medical and lay knowledge about treating scoliosis (spinal curvature), chest clearance to remove obstructions from the lungs during a chest infection and physiotherapy have meant that individuals are often (although not always) able to live full and satisfying lives. (progress.org.uk)
  • Scoliosis in spinal muscular atrophy: review of 63 cases. (medscape.com)
  • Kugelberg Welander spinal muscular atrophy (also known as Wohlfart-Kugelberg-Welander syndrome or mild SMA) is a milder form of SMA, with symptoms typically presenting after age 18 months. (medscape.com)
  • Spinal muscular atrophy type 3 (juvenile form, or Wohlfart-Kugelberg-Welander disease) usually manifests between age 15 months and 19 years. (msdmanuals.com)
  • Type III spinal muscular atrophy (also called Kugelberg-Welander disease or juvenile type) has milder features that typically develop between early childhood and adolescence. (unitedspinal.org)
  • Efficacy and safety of nusinersen in genetically diagnosed infants with presymptomatic spinal muscular atrophy (SMA): Results from the second interim analysis of the ongoing, phase 2 NURTURE study. (biogen.com)
  • Survival Motor Neuron Gene Copy Number Analysis by Exome Sequencing: Assisting Spinal Muscular Atrophy Diagnosis and Carrier Screening. (harvard.edu)
  • For Christoph Keller, it was different: his childhood diagnosis with a form of Spinal Muscular Atrophy only revealed what had been with him since birth. (penguin.co.uk)
  • Quantification of SMN1 and SMN2 genes by capillary electrophoresis for diagnosis of spinal muscular atrophy. (medscape.com)
  • Severe obstructive sleep apnea in a patient with spinal muscle atrophy. (medscape.com)
  • This type of SMA does not appear until later in childhood and is less severe than Types I and II. (hospitalroad.com)
  • The mutation causes severe muscle atrophy due to progressive degeneration of spinal motor neurons, which control the movement of voluntary muscles. (sciencedaily.com)
  • In severe cases of spinal muscular atrophy , the muscles used for breathing and swallowing are affected. (unitedspinal.org)
  • Type I spinal muscular atrophy (also called Werdnig-Hoffman disease) is a severe form of the disorder that is evident at birth or within the first few months of life. (unitedspinal.org)
  • The features of X-linked spinal muscular atrophy appear in infancy and include severe muscle weakness and difficulty breathing. (unitedspinal.org)
  • Spinal Muscular Atrophy (SMA), a leading genetic cause of death in infants, is an autosomal recessive neuromuscular disease characterized by progressive muscle weakness and atrophy. (biomedcentral.com)
  • A study suggests that spinal muscular atrophy (SMA), a genetic neuromuscular disease in infants and children, results primarily from motor circuit dysfunction, not motor neuron or muscle cell dysfunction, as is commonly thought. (neurosciencenews.com)
  • The loss of nerve cells that control muscle movement (motor neurons) leads to atrophy of the muscles in the lower limbs. (medlineplus.gov)
  • Affecting 1 in 3 children worldwide, childhood maltreatment, defined as any form of physical, sexual, or emotional abuse and neglect, is associated with a substantial global mortality and morbidity burden. (ajmc.com)
  • Morbidity associated with these conditions often can be minimized with spinal surgery, as well as with aggressive physical therapy. (medscape.com)
  • Spinal muscular atrophy is a genetic disease of the anterior horn cell with high morbidity rate in childhood. (omeka.net)
  • Simic G. Pathogenesis of proximal autosomal recessive spinal muscular atrophy. (medscape.com)
  • Scientists at The Jackson Laboratory have cloned the gene for the mouse mutation known as neuromuscular degeneration, or nmd, an advance that promises to boost research into such devastating neurological diseases in humans as amyotrophic lateral sclerosis and spinal muscular atrophy. (sciencedaily.com)
  • Similar motor neuron degeneration is implicated in amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). (sciencedaily.com)
  • Currently, various classifications include DSMA1 among general spinal muscular atrophies or distal hereditary motor neuropathies, though the latter has been argued to be more correct. (wikipedia.org)
  • Spinal muscular atrophy type 1 (infantile spinal muscular atrophy, or Werdnig-Hoffmann disease) is also present in utero and becomes symptomatic by about age 6 months. (msdmanuals.com)
  • Respiratory capacity course in patients with infantile spinal muscular atrophy. (medscape.com)
  • Some muscular dystrophies are caused by mutations in genes that make important muscle proteins. (medlineplus.gov)
  • Proporciona un análisis completo de los genes implicados en esta enfermedad utilizando secuenciación de próxima generación (NGS) para comprender completamente el espectro de genes relevantes implicados y su penetrancia alta o intermedia. (igenomix.com)
  • Since then, several types of spinal muscular atrophies have been described based on age when accompanying clinical features appear. (medscape.com)
  • There are five main types of spinal muscular atrophy. (msdmanuals.com)
  • There are many types of spinal muscular atrophy distinguished by the pattern of features, severity of muscle weakness, and age when the muscle problems begin. (unitedspinal.org)
  • This causes progressive muscle weakness and muscle atrophy. (bmj.com)
  • Decreased synaptic vesicle transport in motor neurons, leading to impaired growth of neurons, is thought to contribute to the muscle weakness and atrophy experienced by people with SMA-LED. (medlineplus.gov)
  • In the early 1890s, Werdnig and Hoffman described a disorder of progressive muscular weakness beginning in infancy that resulted in early death, though the age of death was variable. (medscape.com)
  • Soon after, Professor Johann Hoffmann from Heidelberg University presented a paper describing a syndrome of progressive atrophy, weakness, and death during the early childhood period of siblings with genetically normal parents. (medscape.com)
  • Spinal muscular atrophy is a condition that affects the nervous system and caused generalised muscle weakness. (progress.org.uk)
  • The loss of motor neurons leads to weakness and wasting ( atrophy ) of muscles used for activities such as crawling, walking, sitting up, and controlling head movement. (unitedspinal.org)
  • Type II spinal muscular atrophy is characterized by muscle weakness that develops in children between ages 6 and 12 months. (unitedspinal.org)
  • This weakness begins in infancy or early childhood and progresses slowly. (unitedspinal.org)
  • Muscular dystrophies are a group of inherited diseases that cause muscle wasting and weakness. (medlineplus.gov)
  • In people affected by SMA, the loss of motor neurons leads to progressive muscle weakness and atrophy (wasting). (babysfirsttest.org)
  • The cause of spinal muscular atrophy, a condition that leads to muscle weakness, has been uncovered by stem cell research. (belmarrahealth.com)
  • Spinal muscular atrophy (SMA) is caused by successive motor unit degeneration. (medscape.com)
  • During the differentiation stage when the stem cells change into their final shape, two key proteins in motor neurons change in a significant way, which could help explain why these cells are more vulnerable to spinal muscular atrophy degeneration than others. (belmarrahealth.com)
  • Spinal muscular atrophy (SMA) is a progressive, autosomal recessive neuromuscular disorder caused by a mutation of the SMN1 gene. (bmj.com)
  • Spinal muscular atrophy (SMA), the most common form of neurodegenerative disease in childhood, is caused by defects in the SMN1 gene. (medicalxpress.com)
  • Spinal muscular atrophies usually result from autosomal recessive mutations that affect the survival motor neuron 1 ( SMN1 ) gene on the long arm of chromosome 5, most often causing a homozygous deletion of exon 7. (msdmanuals.com)
  • One such form is spinal muscular atrophy with respiratory distress (SMARD). (healthline.com)
  • Under Dr. Kothary's supervision, he studied a genetic muscle-wasting disease that affects mainly young children, called Spinal Muscular Atrophy, or SMA. (ohri.ca)
  • National Institutes of Health-Us Library of Medicine description of SMA: Spinal muscular atrophy is a genetic disorder that affects the control of muscle movement. (unitedspinal.org)
  • The discovery suggests a new way to treat SMA-a devastating childhood motor neuron disease that affects 1 in 6,000 children. (columbia.edu)
  • A just 13 months old, Aviana suffers from Spinal Muscular Atrophy Type One, a rare genetic condition that causes progressive wastage of the muscles. (mamamia.com.au)
  • What are the symptoms of progressive muscular atrophy? (healthline.com)
  • The signs and symptoms of type IV spinal muscular atrophy often occur after age 30. (unitedspinal.org)
  • In some, symptoms present themselves in childhood, and in others symptoms only emerge in adulthood. (belmarrahealth.com)
  • Activation of Muscle-Specific Kinase (MuSK) Reduces Neuromuscular Defects in the Delta7 Mouse Model of Spinal Muscular Atrophy (SMA). (harvard.edu)
  • Marc-Olivier Deguise hopes to change the way that specialists and researchers think about a childhood muscle-wasting disease called spinal muscular atrophy. (ohri.ca)
  • Whole blood survival motor neuron protein levels correlate with severity of denervation in spinal muscular atrophy. (harvard.edu)
  • His mother's cousin gave birth late last year to a boy with a rare, often fatal genetic disease called spinal muscular atrophy. (golf.com)
  • In 1995, the spinal muscular atrophy disease-causing gene, termed the survival motor neuron ( SMN ), was discovered. (medscape.com)
  • Spinal muscular Atrophy (SMA) is a childhood form of Motor Neurone Disease. (abdn.ac.uk)
  • SMA Type One is childhood version of Motor Neurone Disease, and the biggest genetic killer of children under the age of two in Australia. (mamamia.com.au)
  • Spinal muscular atrophy type 1 (SMA1) (Werdnig-Hoffmann disease) is defined by never attaining the ability to sit independently. (doctorbach.com)
  • Patients exposed to childhood maltreatment were at greater risk for developing atopic disease compared with unexposed counterparts, and risk of atopic dermatitis and allergic rhinoconjunctivitis may have been attentuated by misdiagnosis. (ajmc.com)
  • Childhood maltreatment may increase the risk of developing atopic disease, particularly asthma. (ajmc.com)
  • Columbia researchers have discovered how a genetic defect leads to spinal muscular atrophy (SMA), a critical piece of information about the disease that neurologists have been seeking for decades. (columbia.edu)
  • Reference: Bach JR, Baird JS, Plosky D, Nevado J, Weaver B. Spinal muscular atrophy type 1: management and outcomes. (doctorbach.com)
  • To describe survival, hospitalization, speech, and respirator need outcomes for spinal muscular atrophy type 1 (SMA1) patients using noninvasive or tracheostomy ventilation. (doctorbach.com)
  • Patients with SMA type 2 at least temporarily attain the ability to sit unsupported but usually also develop respiratory failure during childhood. (doctorbach.com)
  • Training improves oxidative capacity, but not function in Spinal Muscular Atrophy Type III. (medscape.com)
  • Spinal muscular atrophy type II (SMA2), also called "intermediate" SMA, occurs slightly later than type I, between the ages of 6 and 18 months, and is characterized by the absence of acquisition of autonomous ambulation. (dovepress.com)
  • Individuals with this type of spinal muscular atrophy cannot stand or walk unaided. (unitedspinal.org)
  • Individuals with type III spinal muscular atrophy can stand and walk unaided, but walking and climbing stairs may become increasingly difficult. (unitedspinal.org)
  • Routine sampling and analysis of newborn DNA would allow us to screen for many hundreds of childhood genetic diseases. (medscape.com)
  • There aren't just 13 childhood diseases," continued Geneviève. (medscape.com)
  • Our English-speaking colleagues use the genome to screen for childhood diseases that would benefit from treatment (235 can be treated) but also as a preventive measure and a way of providing early therapeutic education," said Geneviève. (medscape.com)
  • A shift toward a proinflammatory state and alterations in white blood cell counts appear to be caused by the chronic stress of childhood maltreatment, researchers explain, which may increase risk of atopic diseases. (ajmc.com)
  • Recent literature has begun to demonstrate an association between childhood adversity and common atopic diseases, including asthma, atopic dermatitis (AD), and allergic rhinoconjunctivitis, but currently published cohort studies have had a small sample size and not been generalizable to the United Kingdom population. (ajmc.com)
  • However, the same considerations may apply to a broader range of genetic testing applications in various settings - preconception, prenatal, neonatal, or early childhood. (cdc.gov)
  • Hoffmann called the syndrome spinale muskelatrophie (spinal muscular atrophy). (medscape.com)
  • If we are able to identify the 40 newborns affected by spinal muscular atrophy from birth, we can offer these patients gene therapy and stop them from dying at 1 or 2 years of age," said Geneviève. (medscape.com)
  • Unlike the similarly named spinal muscular atrophy , PMA does not occur in children. (healthline.com)
  • According to Spinal Muscular Atrophy Australia Inc. all SMA children appear normal at birth before the deterioration and loss of movement in their limbs begins to become noticeable, usually by the time they reach six months. (mamamia.com.au)
  • In the past, the American College of Obstetrics and Gynecology (ACOG) recommended testing prospective parents for spinal muscular atrophy (SMA) only if their ethnic group showed an increased risk for children inheriting the condition. (hospitalroad.com)
  • Two complications to be aware of are issues with breathing and spinal curvature. (healthline.com)
  • Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy. (harvard.edu)
  • Spinal muscular atrophy has an estimated incidence of 1 case per 15,000 live births. (medscape.com)
  • Spinal muscular atrophy has an estimated incidence of 1 case per 15,000-20,000 live births worldwide. (medscape.com)
  • At what age does progressive muscular atrophy usually appear? (healthline.com)
  • How do doctors diagnose progressive muscular atrophy? (healthline.com)
  • What is the treatment for progressive muscular atrophy? (healthline.com)
  • What is the outlook for people with progressive muscular atrophy? (healthline.com)
  • What causes progressive muscular atrophy? (healthline.com)